Patent Publication Number: US-11382918-B2

Title: Methods for treating Huntington&#39;s Disease

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This application is a U.S. National Stage filing under 35 U.S.C. § 371 of International Application No. PCT/US2018/039775, filed Jun. 27, 2018, which in turn claims priority to U.S. Provisional Application No. 62/525,812, filed Jun. 28, 2017, the entire contents of which are incorporated by reference herein. 
    
    
     The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington&#39;s disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds, forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington&#39;s disease. 
     BACKGROUND 
     Huntington&#39;s Disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. Death, typically caused by pneumonia or coronary artery disease, usually occurs 13 to 15 years after the onset of symptoms. The prevalence of HD is between three and seven individuals per 100,000 in populations of western European descent. In North America, an estimated 30,000 people have HD, while an additional 200,000 people are at risk of inheriting the disease from an affected parent. The disease is caused by an expansion of uninterrupted trinucleotide CAG repeats in the “mutant” huntingtin (Htt) gene, leading to production of HTT (Htt protein) with an expanded poly-glutamine (polyQ) stretch, also known as a “CAG repeat” sequence. There are no current small molecule therapies targeting the underlying cause of the disease, leaving a high unmet need for medications that can be used for treating or ameliorating HD. Consequently, there remains a need to identify and provide a small molecule compound for use in treating or ameliorating HD. 
     All other documents referred to herein are incorporated by reference into the present application as though fully set forth herein. 
     SUMMARY 
     The present description relates to a method or use of a compound for treating or ameliorating HD (Huntington&#39;s Disease) in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): 
                         
or a form thereof, wherein w 1 , w 2 , w 3 , w 4 , w 5 , w 6  and w 7  are as defined herein. In particular, the present description relates to a method of use of a compound of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering an effective amount of the compound or a form or composition thereof, to the subject.
 
    
    
     DETAILED DESCRIPTION 
     The present description relates to a method or use of a compound for treating or ameliorating HD (Huntington&#39;s Disease) in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): 
                         
or a form thereof, wherein:
     w 1  and w 5  are independently C—R a  or N;   w 2  is C—R b  or N;   w 3 , w 4  and w 7  are independently C—R 1 , C—R 2 , C—R a  or N;   w 6  is C—R 1 , C—R 2 , C—R e  or N;   wherein one of w 3 , w 4 , w 6  and w 7  is C—R 1  and one other of w 3 , w 4 , w 6  and w 7  is C—R 2 , provided that,   when w 3  is C—R 1 , then w 6  is C—R 2  and w 4  and w 7  are independently C—R a  or N; or,   when w 3  is C—R 2 , then w 6  is C—R 1  and w 4  and w 7  are independently C—R a  or N; or,   when w 4  is C—R 1 , then w 7  is C—R 2  and w 3  is C—R a  or N and w 6  is C—R e  or N; or,   when w 4  is C—R 2 , then w 7  is C—R 1  and w 3  is C—R a  or N and w 6  is C—R e  or N; and,   wherein any one, two or three of w 1 , w 2 , w 3 , w 4 , w 5 , w 6  and w 7  may optionally be N;   R 1  is C 1-8 alkyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, C 1-8 alkoxy-C 1-8 alkyl-amino, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, amino-C 1-8 alkyl-amino, (amino-C 1-8 alkyl) 2 -amino, (amino-C 1-8 alkyl)(C 1-8 alkyl)amino, C 1-8 alkyl-amino-C 1-8 alkyl-amino, (C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, amino-C 1-8 alkoxy, C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, amino-C 2-8 alkenyl, C 1-8 alkyl-amino-C 2-8 alkenyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkenyl, amino-C 2-8 alkynyl, C 1-8 alkyl-amino-C 2-8 alkynyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkynyl, halo-C 1-8 alkyl-amino, (halo-C 1-8 alkyl) 2 -amino, (halo-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl, hydroxy-C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl-amino, [(hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, [(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl](C 1-8 alkyl)amino, heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl)(C 1-8 alkyl)amino, heterocyclyl-amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino, (heterocyclyl-C 1-8 alkyl) 2 -amino, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C 3-14 cycloalkyl, aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl) 2 -amino, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-C 1-8 alkoxy, heteroaryl-amino, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl) 2 -amino, (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl;   wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with one, two or three R 3  substituents and optionally, with one additional R 4  substituent; or,   wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with one, two, three or four R 3  substituents;   R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino; wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with one, two or three R 6  substituents and optionally, with one additional R 7  substituent;   R a  is, in each instance, independently selected from hydrogen, halogen or C 1-8 alkyl;   R b  is hydrogen, halogen, C 1-8 alkyl or C 1-8 alkoxy;   R c  is hydrogen, halogen or C 1-8 alkyl;   R 3  is, in each instance, independently selected from cyano, halogen, hydroxy, oxo, C 1-8 alkyl, halo-C 1-8 alkyl, C 1-8 alkyl-carbonyl, C 1-8 alkoxy, halo-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl, C 1-8 alkoxy-carbonyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, amino-C 1-8 alkyl-amino, C 1-8 alkyl-amino-C 1-8 alkyl-amino, (C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl]2-amino, (C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, C 1-8 alkoxy-C 1-8 alkyl-amino, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino, C 1-8 alkyl-carbonyl-amino, C 1-8 alkoxy-carbonyl-amino, hydroxy-C 1-8 alkyl, hydroxy-C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl) 2 -amino or (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino;   R 4  is C 3-14 cycloalkyl, C 3-14 cycloalkyl-C 1-8 alkyl, C 3-14 cycloalkyl-amino, aryl-C 1-8 alkyl, aryl-C 1-8 alkoxy-carbonyl, aryl-sulfonyloxy-C 1-8 alkyl, heterocyclyl or heterocyclyl-C 1-8 alkyl; wherein, each instance of C 3-14 cycloalkyl, aryl and heterocyclyl is optionally substituted with one, two or three R 5  substituents;   R 5  is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C 1-8 alkyl, halo-C 1-8 alkyl, C 1-8 alkoxy, halo-C 1-8 alkoxy, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino or C 1-8 alkyl-thio;   R 6  is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C 1-8 alkyl, C 2-8 alkenyl, halo-C 1-8 alkyl, hydroxy-C 1-8 alkyl, C 1-8 alkoxy, halo-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino or C 1-8 alkyl-thio; and,   R 7  is C 3-14 cycloalkyl, C 3-14 cycloalkyl-oxy, aryl, heterocyclyl or heteroaryl; and, wherein the form of the compound is selected from the group consisting of a salt, prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.   In one aspect of the use of a compound of Formula (I), w 1  is C—R a .   In another aspect of the use of a compound of Formula (I), w 1  is N.   In one aspect of the use of a compound of Formula (I), w 2  is C—R b .   In another aspect of the use of a compound of Formula (I), w 2  is N.   In one aspect of the use of a compound of Formula (I), w 3  is C—R a .   In another aspect of the use of a compound of Formula (I), w 3  is N.   In one aspect of the use of a compound of Formula (I), w 4  is C—R a .   In another aspect of the use of a compound of Formula (I), w 4  is N.   In one aspect of the use of a compound of Formula (I), w 5  is C—R a .   In another aspect of the use of a compound of Formula (I), w 5  is N.   In one aspect of the use of a compound of Formula (I), w 6  is C—R e .   In another aspect of the use of a compound of Formula (I), w 6  is N.   In one aspect of the use of a compound of Formula (I), w 7  is C—R a .   In another aspect of the use of a compound of Formula (I), w 7  is N.   In one aspect of the use of a compound of Formula (I), w 3  is C—R 1  and w 6  is C—R 2 .   In another aspect of the use of a compound of Formula (I), w 3  is C—R 2  and w 6  is C—R 1 .   In one aspect of the use of a compound of Formula (I), w 4  is C—R 1  and w 7  is C—R 2 .   In another aspect of the use of a compound of Formula (I), w 4  is C—R 2  and w 7  is C—R 1 .   In one aspect of the use of a compound of Formula (I), w 3  is C—R 1 , w 6  is C—R 2  and w 1 , w 4 , w 5  and w 7  are independently C—R a  or N and w 2  is C—R b  or N.   In another aspect of the use of a compound of Formula (I), w 3  is C—R 2 , w 6  is C—R 1  and w 1 , w 4 , w 5  and w 7  are independently C—R a  or N and w 2  is C—R b  or N.   In one aspect of the use of a compound of Formula (I), w 4  is C—R 1 , w 7  is C—R 2 , w 1 , w 3  and w 5  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N.   In another aspect of the use of a compound of Formula (I), w 4  is C—R 2 , w 7  is C—R 1 , w 1 , w 3  and w 5  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N.   In one aspect of the use of a compound of Formula (I), w 1  and w 2  are N.   In one aspect of the use of a compound of Formula (I), w 1  and w 3  are N.   In one aspect of the use of a compound of Formula (I), w 1  and w 4  are N.   In one aspect of the use of a compound of Formula (I), w 1  and w 5  are N.   In one aspect of the use of a compound of Formula (I), w 1  and w 6  are N.   In one aspect of the use of a compound of Formula (I), w 1  and w 7  are N.   In one aspect of the use of a compound of Formula (I),   R 1  is C 1-8 alkyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, C 1-8 alkoxy-C 1-8 alkyl-amino, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, amino-C 1-8 alkyl-amino, (amino-C 1-8 alkyl) 2 -amino, (amino-C 1-8 alkyl)(C 1-8 alkyl)amino, C 1-8 alkyl-amino-C 1-8 alkyl-amino, (C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, amino-C 1-8 alkoxy, C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, amino-C 2-8 alkenyl, C 1-8 alkyl-amino-C 2-8 alkenyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkenyl, amino-C 2-8 alkynyl, C 1-8 alkyl-amino-C 2-8 alkynyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkynyl, halo-C 1-8 alkyl-amino, (halo-C 1-8 alkyl) 2 -amino, (halo-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl, hydroxy-C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl-amino, [(hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, [(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl](C 1-8 alkyl)amino, heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl)(C 1-8 alkyl)amino, heterocyclyl-amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino, (heterocyclyl-C 1-8 alkyl) 2 -amino, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C 3-14 cycloalkyl, aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl) 2 -amino, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-C 1-8 alkoxy, heteroaryl-amino, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl) 2 -amino, (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl; wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is amino, (C 1-8 alkyl) 2 -amino, C 1-8 alkoxy-C 1-8 alkyl-amino, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, amino-C 1-8 alkyl-amino, (amino-C 1-8 alkyl) 2 -amino, (amino-C 1-8 alkyl)(C 1-8 alkyl)amino, C 1-8 alkyl-amino-C 1-8 alkyl-amino, (C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, amino-C 1-8 alkoxy, C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, amino-C 2-8 alkenyl, C 1-8 alkyl-amino-C 2-8 alkenyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkenyl, amino-C 2-8 alkynyl, C 1-8 alkyl-amino-C 2-8 alkynyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkynyl, halo-C 1-8 alkyl-amino, (halo-C 1-8 alkyl) 2 -amino, (halo-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl, hydroxy-C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl-amino, [(hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, [(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl](C 1-8 alkyl)amino, heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl)(C 1-8 alkyl)amino, heterocyclyl-amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino, (heterocyclyl-C 1-8 alkyl) 2 -amino, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C 3-14 cycloalkyl, aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl) 2 -amino, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-C 1-8 alkoxy, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl) 2 -amino, (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl; wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is C 1-8 alkyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, C 1-8 alkoxy-C 1-8 alkyl-amino, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, amino-C 1-8 alkyl-amino, (amino-C 1-8 alkyl) 2 -amino, (amino-C 1-8 alkyl)(C 1-8 alkyl)amino, C 1-8 alkyl-amino-C 1-8 alkyl-amino, (C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, amino-C 1-8 alkoxy, C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, amino-C 2-8 alkenyl, C 1-8 alkyl-amino-C 2-8 alkenyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkenyl, amino-C 2-8 alkynyl, C 1-8 alkyl-amino-C 2-8 alkynyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkynyl, halo-C 1-8 alkyl-amino, (halo-C 1-8 alkyl) 2 -amino, (halo-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl, hydroxy-C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl-amino, [(hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino or [(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl](C 1-8 alkyl)amino.   In another aspect of the use of a compound of Formula (I),   R 1  is heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl)(C 1-8 alkyl)amino, heterocyclyl-amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino, (heterocyclyl-C 1-8 alkyl) 2 -amino, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C 3-14 cycloalkyl, aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl) 2 -amino, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-C 1-8 alkoxy, heteroaryl-amino, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl) 2 -amino, (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl; wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl)(C 1-8 alkyl)amino, heterocyclyl-amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino, (heterocyclyl-C 1-8 alkyl) 2 -amino, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl or heterocyclyl-carbonyl-oxy; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl optionally substituted with one, two or three R 3  substituents and optionally, with one additional R 4  substituents; or, optionally, with one, two, three or four R 3  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is C 3-14 cycloalkyl optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl) 2 -amino, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl; wherein, each instance of aryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is aryl-C 1-8 alkyl-amino optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-C 1-8 alkoxy, heteroaryl-amino, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl) 2 -amino, (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl; wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heteroaryl optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I),   R 1  is heterocyclyl selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 3,6-dihydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, 1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolyl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazinyl, (8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazinyl, (8aS)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazinyl, (8aR)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazinyl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, (3aR,4aR,7aS)-hexahydro-1H-cyclobuta[1,2-c:1,4-c′]dipyrrol-(3H)-yl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,6-diazabicyclo[3.2.0]heptyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 4,7-diazaspiro[2.5]octyl, 2,6-diazaspiro[3.4]octyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl or 6,9-diazaspiro[4.5]decyl; wherein, each instance of heterocyclyl is optionally substituted with one, two or three R 3  substituents and optionally, with one additional R 4  substituent; or, optionally, with one, two, three or four R 3  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is heterocyclyl selected from azetidin-1-yl, tetrahydrofuran-3-yl, pyrrolidin-1-yl, piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, 1,4-diazepan-1-yl, 3,6-dihydropyridin-4-yl, 1,2,5,6-tetrahydropyridin-5-yl, 1,2,3,6-tetrahydropyridin-4-yl, hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5 (1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl, octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, hexahydropyrrolo[1,2-a]pyrazin-6(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl, (8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl, (8aS)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl, (8aR)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazin-2-yl, (3aR,4aR,7aS)-hexahydro-1H-cyclobuta[1,2-c:1,4-c′]dipyrrol-2(3H)-yl, 3-azabicyclo[3.1.0]hex-3-yl, 8-azabicyclo[3.2.1]oct-3-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl, 8-azabicyclo[3.2.1]oct-2-en-3-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-en-3-yl, 9-azabicyclo[3.3.1]non-3-yl, (1R,5S)-9-azabicyclo[3.3.1]non-3-yl, 2,5-diazabicyclo[2.2.1]hept-2-yl, (1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl, 2,5-diazabicyclo[2.2.2]oct-2-yl, 3,6-diazabicyclo[3.2.0]hept-3-yl, 3,8-diazabicyclo[3.2.1]oct-3-yl, (1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl, 1,4-diazabicyclo[3.2.2]non-4-yl, azaspiro[3.3]hept-2-yl, 2,6-diazaspiro[3.3]hept-2-yl, 4,7-diazaspiro[2.5]oct-7-yl, 2,6-diazaspiro[3.4]oct-2-yl, 2,7-diazaspiro[3.5]non-2-yl, 2,7-diazaspiro[3.5]non-7-yl, 5,8-diazaspiro[3.5]non-8-yl, 2,7-diazaspiro[4.4]non-2-yl or 6,9-diazaspiro[4.5]dec-9-yl; wherein, each instance of heterocyclyl is optionally substituted with one, two or three R 3  substituents and optionally, with one additional R 4  substituent; or, optionally, with one, two, three or four R 3  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is substituted heterocyclyl selected from (3R)-3-pyrrolidin-1-ylpyrrolidin-1-yl, 1-methylpiperidin-4-yl, 1-ethylpiperidin-4-yl, 2,2,6,6-tetramethylpiperidin-4-yl, (3 S)-3-methylpiperazin-1-yl, 4-methylpiperazin-1-yl, 4-ethylpiperazin-1-yl, 3-(trifluoromethyl)piperazin-1-yl, 1-tert-butoxy-carbonyl-3,6-dihydropyridin-4-yl, 1-ethyl-1,2,3,6-tetrahydropyridin-4-yl, 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl, 4-methyl-1,4-diazepan-1-yl, (3aS,6aS)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, (3aS,6aS)-5-methylhexahydropyrrolo[3,4-b]pyrrol-1 (2H)-yl, (3 aR, 6aR)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5 (1H)-yl, (3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-5-(2-hydroxyethyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-5-(propan-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-5-ethylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (4aR,7aR)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-1-ethyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-1-(2-hydroxyethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-1-(2-hydroxyethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (7R,8aS)-7-hydroxyhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aS)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl, (8aR)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl, (8aS)-8a-methyloctahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-8a-methyloctahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (1R,5S,6s)-6-(dimethylamino)-3-azabicyclo[3.1.0]hex-3-yl, (1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl, 9-methyl-9-azabicyclo[3.3.1]non-3-yl, (3-exo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl, (1R,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl, (1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl, (1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl or 6-methyl-2,6-diazaspiro[3.3]hept-2-yl.   In one aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-C 1-8 alkyl, wherein heterocyclyl is selected from morpholinyl, piperidinyl, piperazinyl, imidazolyl or pyrrolidinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-C 1-8 alkyl selected from morpholin-4-yl-methyl, morpholin-4-yl-ethyl, morpholin-4-yl-propyl, piperidin-1-yl-methyl, piperazin-1-yl-methyl, piperazin-1-yl-ethyl, piperazin-1-yl-propyl, piperazin-1-yl-butyl, imidazol-1-yl-methyl, imidazol-1-yl-ethyl, imidazol-1-yl-propyl, imidazol-1-yl-butyl, pyrrolidin-1-yl-methyl, pyrrolidin-1-yl-ethyl, pyrrolidin-1-yl-propyl or pyrrolidin-1-yl-butyl; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-C 1-8 alkoxy, wherein heterocyclyl is selected from pyrrolidinyl, piperidinyl or morpholinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-C 1-8 alkoxy selected from pyrrolidin-2-yl-methoxy, pyrrolidin-2-yl-ethoxy, pyrrolidin-1-yl-methoxy, pyrrolidin-1-yl-ethoxy, piperidin-1-yl-methoxy, piperidin-1-yl-ethoxy, morpholin-4-yl-methoxy or morpholin-4-yl-ethoxy; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-amino, wherein heterocyclyl is selected from azetidinyl, pyrrolidinyl, piperidinyl, 9-azabicyclo[3.3.1]nonyl or (1R,5S)-9-azabicyclo[3.3.1]nonyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-amino selected from azetidin-3-yl-amino, pyrrolidin-3-yl-amino, piperidin-4-yl-amino, 9-azabicyclo[3.3.1]non-3-yl-amino, (1R,5S)-9-azabicyclo[3.3.1]non-3-yl-amino, 9-methyl-9-azabicyclo[3.3.1]non-3-yl-amino, (3-exo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl-amino or (1R,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl-amino; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is (heterocyclyl)(C 1-8 alkyl)amino, wherein heterocyclyl is selected from pyrrolidinyl or piperidinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is (heterocyclyl)(C 1-8 alkyl)amino selected from (pyrrolidin-3-yl)(methyl)amino or (piperidin-4-yl)(methyl)amino; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-amino-C 1-8 alkyl, wherein heterocyclyl is selected from tetrahydrofuranyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-amino-C 1-8 alkyl, selected from 3-(tetrahydrofuran-3-yl-amino)propyl; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, wherein heterocyclyl is selected from tetrahydrofuranyl, thienyl or pyridinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, selected from 3-[(tetrahydrofuran-2-ylmethyl)amino]propyl, 3-[(thienyl-3-ylmethyl)amino]propyl, 3-[(pyridin-2-ylmethyl)amino]propyl or 3-[(pyridin-4-ylmethyl)amino]propyl; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-oxy, wherein heterocyclyl is selected from pyrrolidinyl or piperidinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-oxy selected from pyrrolidin-3-yl-oxy or piperidin-4-yl-oxy; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-carbonyl, wherein heterocyclyl is selected from piperazinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-carbonyl selected from piperazin-1-yl-carbonyl; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-carbonyl-oxy, wherein heterocyclyl is selected from piperazinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl-carbonyl-oxy selected from piperazin-1-yl-carbonyl-oxy; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is C 3-14 cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl or cycloheptyl; wherein, each instance of C 3-14 cycloalkyl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is C 3-8 cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl or cycloheptyl; wherein, each instance of C 3-8 cycloalkyl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is aryl-C 1-8 alkyl-amino-C 1-8 alkyl, wherein aryl is selected from phenyl; and, wherein, each instance of aryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is aryl-C 1-8 alkyl-amino-C 1-8 alkyl selected from 3-(benzylamino)propyl; wherein, each instance of aryl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heteroaryl, wherein heteroaryl is selected from pyridinyl; and, wherein, each instance of heteroaryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heteroaryl selected from pyridin-4-yl; wherein, each instance of heteroaryl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heteroaryl-C 1-8 alkyl, wherein heteroaryl is selected from 1H-imidazolyl; and, wherein, each instance of heteroaryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heteroaryl-C 1-8 alkyl selected from 1H-imidazol-1-yl-methyl; wherein, each instance of heteroaryl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, wherein heteroaryl is selected from pyridinyl; and, wherein, each instance of heteroaryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino selected from (pyridin-3-ylmethyl)(methyl)amino; wherein, each instance of heteroaryl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 1  is heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, wherein heteroaryl is selected from thienyl or pyridinyl; and, wherein, each instance of heteroaryl is optionally substituted with R 3  and R 4  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl selected from thien-3-yl-methyl-amino-propyl, pyridin-2-yl-methyl-amino-propyl, pyridin-3-yl-methyl-amino-propyl or pyridin-4-yl-methyl-amino-propyl; wherein, each instance of heteroaryl is optionally substituted with R 3  and R 4  substituents.   In one aspect of the use of a compound of Formula (I), R 3  is selected from cyano, halogen, hydroxy, oxo, C 1-8 alkyl, halo-C 1-8 alkyl, C 1-8 alkyl-carbonyl, C 1-8 alkoxy, halo-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl, C 1-8 alkoxy-carbonyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, amino-C 1-8 alkyl-amino, C 1-8 alkyl-amino-C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, C 1-8 alkoxy-C 1-8 alkyl-amino, C 1-8 alkyl-carbonyl-amino, C 1-8 alkoxy-carbonyl-amino, hydroxy-C 1-8 alkyl, hydroxy-C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl) 2 -amino or (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino.   In another aspect of the use of a compound of Formula (I), R 3  is selected from cyano, halogen, hydroxy, oxo, C 1-8 alkyl, halo-C 1-8 alkyl, C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl, C 1-8 alkoxy-carbonyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl-amino, C 1-8 alkoxy-C 1-8 alkyl-amino, C 1-8 alkoxy-carbonyl-amino, hydroxy-C 1-8 alkyl, hydroxy-C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl) 2 -amino or (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino.   In one aspect of the use of a compound of Formula (I), R 3  is C 1-8 alkyl selected from methyl, ethyl, propyl, isopropyl or tert-butyl.   In another aspect of the use of a compound of Formula (I), R 3  is C 1-8 alkyl selected from ethyl, propyl, isopropyl or tert-butyl.   In one aspect of the use of a compound of Formula (I), R 3  is halo-C 1-8 alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, halo-ethyl, trihalo-propyl, dihalo-propyl or halo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.   In another aspect of the use of a compound of Formula (I), R 3  is halo-C 1-8 alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, trihalo-propyl or dihalo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.   In one aspect of the use of a compound of Formula (I), R 3  is hydroxy-C 1-8 alkyl selected from hydroxy-methyl, hydroxy-ethyl, hydroxy-propyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.   In another aspect of the use of a compound of Formula (I), R 3  is hydroxy-C 1-8 alkyl selected from hydroxy-methyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.   In one aspect of the use of a compound of Formula (I), R 3  is C 1-8 alkoxy selected from methoxy, ethoxy, propoxy or isopropoxy.   In one aspect of the use of a compound of Formula (I), R 3  is halo-C 1-8 alkoxy selected from trihalo-methoxy, dihalo-methoxy, halo-methoxy, trihalo-ethoxy, dihalo-ethoxy, halo-ethoxy, trihalo-propoxy, dihalo-propoxy or halo-propoxy; wherein, halo is selected from fluoro, chloro, bromo or iodo.   In one aspect of the use of a compound of Formula (I), R 3  is C 1-8 alkoxy-carbonyl-amino selected from methoxy-carbonyl-amino, ethoxy-carbonyl-amino, propoxy-carbonyl-amino, isopropoxy-carbonyl-amino, tert-butoxy-carbonyl-amino.   In one aspect of the use of a compound of Formula (I), R 4  is C 3-14 cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; wherein, each instance of C 3-14 cycloalkyl is optionally substituted with R 5  substituents.   In another aspect of the use of a compound of Formula (I), R 4  is C 3-8 cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; wherein, each instance of C 3-8 cycloalkyl is optionally substituted with R 5  substituents.   In one aspect of the use of a compound of Formula (I), R 4  is C 3-14 cycloalkyl-C 1-8 alkyl, wherein C 3-14 cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; and, wherein, each instance of C 3-14 cycloalkyl is optionally substituted with R 5  substituents.   In another aspect of the use of a compound of Formula (I), R 4  is C 3-8 cycloalkyl-C 1-8 alkyl, wherein C 3-8 cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; and, wherein, each instance of C 3-8 cycloalkyl is optionally substituted with R 5  substituents.   In one aspect of the use of a compound of Formula (I), R 4  is C 3-14 cycloalkyl-amino, wherein C 3-14 cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; and, wherein, each instance of C 3-14 cycloalkyl is optionally substituted with R 5  substituents.   In another aspect of the use of a compound of Formula (I), R 4  is C 3-8 cycloalkyl-amino, wherein C 3-8 cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; and, wherein, each instance of C 3-8 cycloalkyl is optionally substituted with R 5  substituents.   In one aspect of the use of a compound of Formula (I), R 4  is aryl-C 1-8 alkyl, aryl-C 1-8 alkoxy-carbonyl or aryl-sulfonyloxy-C 1-8 alkyl, wherein aryl is selected from phenyl; and, wherein, each instance of aryl is optionally substituted with R 5  substituents.   In another aspect of the use of a compound of Formula (I), R 4  is aryl-C 1-8 alkyl or aryl-C 1-8 alkoxy-carbonyl, wherein each instance of aryl is optionally substituted with R 5  substituents.   In one aspect of the use of a compound of Formula (I), R 4  is heterocyclyl selected from oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,3-dioxanyl or morpholinyl, wherein each instance of heterocyclyl is optionally substituted with R 5  substituents.   In another aspect of the use of a compound of Formula (I), R 4  is heterocyclyl selected from oxetan-3-yl, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 1,3-dioxan-5-yl or morpholin-4-yl, wherein each instance of heterocyclyl is optionally substituted with R 5  substituents.   In one aspect of the use of a compound of Formula (I), R 4  is heterocyclyl-C 1-8 alkyl, wherein each instance of heterocyclyl is selected from pyrrolidinyl or piperidinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R 5  substituents.   In another aspect of the use of a compound of Formula (I), R 4  is heterocyclyl-C 1-8 alkyl selected from pyrrolidin-1-yl-C 1-8 alkyl or piperidin-1-yl-C 1-8 alkyl, wherein each instance of heterocyclyl is optionally substituted with R 5  substituents.   In one aspect of the use of a compound of Formula (I), R 5  is selected from halogen, hydroxy, cyano, nitro, halo-C 1-8 alkyl, C 1-8 alkoxy, halo-C 1-8 alkoxy, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino or C 1-8 alkyl-thio; wherein, halogen and halo is selected from fluoro, chloro, bromo or iodo.   In one aspect of the use of a compound of Formula (I), R 5  is hydroxy.   In one aspect of the use of a compound of Formula (I), R 5  is C 1-8 alkyl selected from methyl, ethyl, propyl, isopropyl, n-butyl or tert-butyl.   In another aspect of the use of a compound of Formula (I), R 5  is C 1-8 alkyl selected from ethyl, propyl, isopropyl or tert-butyl.   In one aspect of the use of a compound of Formula (I), R 5  is halo-C 1-8 alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, halo-ethyl, trihalo-propyl, dihalo-propyl or halo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.   In one aspect of the use of a compound of Formula (I), R 5  is C 1-8 alkoxy selected from methoxy, ethoxy, propoxy or isopropoxy.   In one aspect of the use of a compound of Formula (I), R 5  is halo-C 1-8 alkoxy selected from trihalo-methoxy, dihalo-methoxy, halo-methoxy, trihalo-ethoxy, dihalo-ethoxy, halo-ethoxy, trihalo-propoxy, dihalo-propoxy or halo-propoxy; wherein, halo is selected from fluoro, chloro, bromo or iodo.   In one aspect of the use of a compound of Formula (I), R 2  is aryl selected from phenyl optionally substituted with one, two or three R 6  substituents and optionally, with one additional R 7  substituent.   In one aspect of the use of a compound of Formula (I), R 2  is aryl-amino, wherein aryl is selected from phenyl; and, wherein, each instance of aryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I), R 2  is aryl-amino selected from phenyl-amino; wherein, each instance of aryl is optionally substituted with R 6  and R 7  substituents.   In one aspect of the use of a compound of Formula (I), R 2  is aryl-amino-carbonyl, wherein aryl is selected from phenyl; and, wherein, each instance of aryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I), R 2  is aryl-amino-carbonyl selected from phenyl-amino-carbonyl; wherein, each instance of aryl is optionally substituted with R 6  and R 7  substituents.   In one aspect of the use of a compound of Formula (I),   R 2  is heterocyclyl selected from 1,2,3,6-tetrahydropyridinyl, 1,3-benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl; wherein, each instance of heterocyclyl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 2  is heterocyclyl selected from 1,2,3,6-tetrahydropyridin-4-yl, 1,3-benzodioxol-5-yl or 2,3-dihydro-1,4-benzodioxin-6-yl; wherein, each instance of heterocyclyl is optionally substituted with R 6  and R 7  substituents.   In one aspect of the use of a compound of Formula (I),   R 2  is heteroaryl optionally substituted with one, two or three R 6  substituents and optionally, with one additional R 7  substituent.   In one aspect of the use of a compound of Formula (I),   R 2  is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl, quinazolinyl, quinoxalinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, pyrazolo[4,3-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, imidazo[1,2-a]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-b]pyridazinyl, pyrido[1,2-a]pyrimidinyl or pyrido[1,2-a]pyrimidinone; wherein, each instance of heteroaryl is optionally substituted with one, two or three R 6  substituents and optionally, with one additional R 7  substituent.   In another aspect of the use of a compound of Formula (I),   R 2  is heteroaryl selected from thien-2-yl, thien-3-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, 1,3-thiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-4-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indazol-5-yl, 2H-indazol-5-yl, indolizin-2-yl, benzofuran-2-yl, benzofuran-5-yl, benzothien-2-yl, benzothien-3-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-6-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 9H-purin-8-yl, quinazolin-6-yl, quinoxalin-2-yl, furo[3,2-b]pyridin-2-yl, furo[3,2-c]pyridin-2-yl, furo[2,3-c]pyridin-2-yl, thieno[3,2-c]pyridin-2-yl, thieno[2,3-d]pyrimidin-6-yl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1H-pyrrolo[2,3-c]pyridin-4-yl, pyrrolo[1,2-a]pyrimidin-7-yl, pyrrolo[1,2-a]pyrazin-7-yl, pyrrolo[1,2-b]pyridazin-2-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-5-yl, pyrazolo[1,5-a]pyrazin-2-yl, pyrazolo[4,3-b]pyridin-5-yl, pyrazolo[3,4-c]pyridin-5-yl, imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[1,2-a]pyrimidin-6-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[1,2-b]pyridazin-6-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[2,1-b][1,3]thiazol-6-yl, imidazo[2,1-b][1,3,4]thiadiazol-6-yl, [1,3]oxazolo[4,5-b]pyridin-2-yl, [1,2,4]triazolo[1,5-a]pyridin-6-yl, [1,2,4]triazolo[1,5-a]pyrimidin-6-yl, [1,2,4]triazolo[1,5-b]pyridazin-6-yl, pyrido[1,2-a]pyrimidin-4-yl or pyrido[1,2-a]pyrimidin-4-one; wherein, each instance of heteroaryl is optionally substituted with one, two or three R 6  substituents and optionally, with one additional R 7  substituent.   In another aspect of the use of a compound of Formula (I),   R 2  is substituted heteroaryl selected from 4-methylthien-2-yl, 1-methyl-1H-pyrazol-3-yl, 4-methyl-1H-pyrazol-3-yl, 1-phenyl-1H-pyrazol-3-yl, 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl, 1-phenyl-1H-imidazol-4-yl, 2-methyl-1-(pyridin-2-yl)-1H-imidazol-4-yl, 4-methyl-1,3-thiazol-2-yl, 4-(trifluoromethyl)-1,3-thiazol-2-yl, 4-phenyl-1,3-thiazol-2-yl, 5-phenyl-1,2,4-oxadiazol-3-yl, 3-fluoropyridin-4-yl, 6-fluoropyridin-2-yl, 2-chloropyridin-4-yl, 4-chloropyridin-3-yl, 5-chloropyridin-2-yl, 6-methylpyridin-3-yl, 2-(trifluoromethyl)pyridin-3-yl, 4-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)pyridin-2-yl, 2-methoxypyridin-4-yl, 4-methoxypyridin-3-yl, 6-methoxypyridin-2-yl, 2-ethoxypyridin-3-yl, 6-ethoxypyridin-2-yl, 6-(propan-2-yloxy)pyridin-2-yl, 6-(dimethylamino)pyridin-3-yl, 6-(methyl sulfanyl)pyridin-2-yl, 6-(cyclobutyloxy)pyridin-2-yl, 6-(pyrrolidin-1-yl)pyridin-2-yl, (5-fluoro-6-hydroxy)pyridin-3-yl, 2-methylpyrimidin-4-yl, 2-(propan-2-yl)pyrimidin-4-yl, 2-cyclopropylpyrimidin-4-yl, 1-methyl-1H-indol-3-yl, 1,7-dimethyl-1H-indazol-5-yl, 2-methyl-2H-indazol-5-yl, 2,7-dimethyl-2H-indazol-5-yl, 7-fluoro-2-methyl-2H-indazol-5-yl, 2-methyl-1-benzofuran-5-yl, 1-methyl-1H-benzimidazol-2-yl, 4-methyl-1H-benzimidazol-2-yl 5-fluoro-1H-benzimidazol-2-yl, 4-fluoro-1,3-benzoxazol-2-yl, 5-fluoro-1,3-benzoxazol-2-yl, 4-chloro-1,3-benzoxazol-2-yl, 4-iodo-1,3-benzoxazol-2-yl, 2-methyl-1,3-benzoxazol-6-yl, 4-methyl-1,3-benzoxazol-2-yl, 4-(trifluoromethyl)-1,3-benzoxazol-2-yl, 7-(trifluoromethyl)-1,3-benzoxazol-2-yl, 2-methyl-1,3-benzothiazol-2-yl, 2-methyl-1,3-benzothiazol-5-yl, 2-methyl-1,3-benzothiazol-6-yl, 4-chloro-1,3-benzothiazol-2-yl, 7-chloro-1,3-benzothiazol-2-yl, 4-(trifluoromethyl)-1,3-benzothiazol-2-yl, (4-hydroxy-2-methyl)quinazolin-6-yl, 5-methylfuro[3,2-b]pyridin-2-yl, 4,6-dimethylfuro[3,2-c]pyridin-2-yl, 5,7-dimethylfuro[2,3-c]pyridin-2-yl, 4,6-dimethylthieno[3,2-c]pyridin-2-yl, 2,4-dimethylthieno[2,3-d]pyrimidin-6-yl, 1-methylpyrrolo[1,2-a]pyrazin-7-yl, 3-methylpyrrolo[1,2-a]pyrazin-7-yl, 1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl, 2-methylpyrrolo[1,2-b]pyridazin-2-yl, 2-methylpyrazolo[1,5-a]pyridin-5-yl, 5-methylpyrazolo[1,5-a]pyridin-2-yl, 4-(dimethyl amino)-6-methylpyrazolo[1,5-a]pyrazin-2-yl, 4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl, 4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl, 1,7-dimethyl-1H-pyrazolo[4,3-b]pyridin-5-yl, 1,7-dimethyl-1H-pyrazolo[3,4-c]pyridin-5-yl, 2,7-dimethyl-2H-pyrazolo[3,4-c]pyridin-5-yl, 2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl, 2-chloroimidazo[2,1-b][1,3]thiazol-6-yl, 2-methylimidazo[2,1-b][1,3]thiazol-6-yl, 3-methylimidazo[2,1-b][1,3]thiazol-6-yl, 2-ethylimidazo[2,1-b][1,3]thiazol-6-yl, 2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl, 6-cyanoimidazo[1,2-a]pyridin-2-yl (also referred to as 2-imidazo[1,2-a]pyridine-6-carbonitrile), 6-fluoroimidazo[1,2-a]pyridin-2-yl, 8-fluoroimidazo[1,2-a]pyridin-2-yl, 6,8-difluoroimidazo[1,2-a]pyridin-2-yl, 7-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl, 8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl, 6-chloroimidazo[1,2-a]pyridin-2-yl, 7-chloroimidazo[1,2-a]pyridin-2-yl, 8-chloroimidazo[1,2-a]pyridin-2-yl, 8-bromoimidazo[1,2-a]pyridin-2-yl, 2-methylimidazo[1,2-a]pyridin-2-yl, 5-methylimidazo[1,2-a]pyridin-2-yl, 6-methylimidazo[1,2-a]pyridin-2-yl, 7-methylimidazo[1,2-a]pyridin-2-yl, 8-methylimidazo[1,2-a]pyridin-2-yl, 7-ethylimidazo[1,2-a]pyridin-2-yl, 8-ethylimidazo[1,2-a]pyridin-2-yl, 6,8-dimethylimidazo[1,2-a]pyridin-2-yl, 8-ethyl-6-methylimidazo[1,2-a]pyridin-2-yl, 7-methoxyimidazo[1,2-a]pyridin-2-yl, 8-methoxyimidazo[1,2-a]pyridin-2-yl, 6-fluoro-8-methylimidazo[1,2-a]pyridin-2-yl, 8-fluoro-6-methylimidazo[1,2-a]pyridin-2-yl, 8-chloro-6-methylimidazo[1,2-a]pyridin-2-yl, 6-methyl-8-nitroimidazo[1,2-a]pyridin-2-yl, 8-cyclopropylimidazo[1,2-a]pyridin-2-yl, 2-methylimidazo[1,2-a]pyridin-6-yl, 2-ethylimidazo[1,2-a]pyridin-6-yl, 2,3-dimethylimidazo[1,2-a]pyridin-6-yl, 2,8-dimethylimidazo[1,2-a]pyridin-6-yl, 2-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl, 8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl, 8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl, 6-fluoroimidazo[1,2-a]pyrimidin-2-yl, 6-chloroimidazo[1,2-a]pyrimidin-2-yl, 6-methylimidazo[1,2-a]pyrimidin-2-yl, 7-methylimidazo[1,2-a]pyrimidin-2-yl, 2-methylimidazo[1,2-a]pyrimidin-6-yl, 6-methylimidazo[1,2-b]pyridazin-2-yl, 2-methylimidazo[1,2-b]pyridazin-6-yl, 2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl, 6-methylimidazo[1,2-a]pyrazin-2-yl, 8-methylimidazo[1,2-a]pyrazin-2-yl, 6,8-dimethylimidazo[1,2-a]pyrazin-2-yl, 6-chloro-8-methylimidazo[1,2-a]pyrazin-2-yl, 6-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyrazin-2-yl, 8-(methylsulfanyl)imidazo[1,2-a]pyrazin-2-yl, 2-methylimidazo[2,1-b][1,3]thiazol-6-yl, 3-methylimidazo[2,1-b][1,3]thiazol-6-yl, 2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl, 2-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl, 2-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl, 2-methyl-[1,2,4]triazolo[1,5-b]pyridazin-6-yl or 4H,4′H-2,7′-bipyrido[1,2-a]pyrimidine-4,4′-dione.   In another aspect of the use of a compound of Formula (I),   R 2  is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl, quinazolinyl or quinoxalinyl; wherein, each instance of heteroaryl is optionally substituted with one, two or three R 6  substituents and optionally, with one additional R 7  substituent.   In another aspect of the use of a compound of Formula (I),   R 2  is heteroaryl selected from furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, pyrazolo[4,3-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, imidazo[1,2-a]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-b]pyridazinyl, pyrido[1,2-a]pyrimidinyl or pyrido[1,2-a]pyrimidinone; wherein, each instance of heteroaryl is optionally substituted with one, two or three R 6  substituents and optionally, with one additional R 7  substituent.   In one aspect of the use of a compound of Formula (I), R 2  is heteroaryl-amino, wherein heteroaryl is selected from pyridinyl or pyrimidinyl; and, wherein, each instance of heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I), R 2  is heteroaryl-amino selected from pyridin-2-yl-amino, pyridin-3-yl-amino or pyrimidin-2-yl-amino; wherein, each instance of heteroaryl is optionally substituted with R 6  and R 7  substituents.   In one aspect of the use of a compound of Formula (I), R 6  is selected from halogen, hydroxy, cyano, nitro, C 1-8 alkyl, halo-C 1-8 alkyl, hydroxy-C 1-8 alkyl, C 1-8 alkoxy, halo-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino or C 1-8 alkyl-thio; wherein, halogen and halo is selected from fluoro, chloro, bromo or iodo.   In one aspect of the use of a compound of Formula (I), R 6  is C 1-8 alkyl selected from methyl, ethyl, propyl, isopropyl or tert-butyl.   In another aspect of the use of a compound of Formula (I), R 6  is C 1-8 alkyl selected from ethyl, propyl, isopropyl or tert-butyl.   In one aspect of the use of a compound of Formula (I), R 6  is C 2-8 alkenyl selected from ethenyl, allyl or buta-1,3-dienyl.   In another aspect of the use of a compound of Formula (I), R 6  is C 2-8 alkenyl selected from ethenyl or allyl.   In one aspect of the use of a compound of Formula (I), R 6  is halo-C 1-8 alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, halo-ethyl, trihalo-propyl, dihalo-propyl or halo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.   In one aspect of the use of a compound of Formula (I), R 6  is hydroxy-C 1-8 alkyl selected from hydroxy-methyl, hydroxy-ethyl, hydroxy-propyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.   In another aspect of the use of a compound of Formula (I), R 6  is hydroxy-C 1-8 alkyl selected from hydroxy-methyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.   In one aspect of the use of a compound of Formula (I), R 6  is C 1-8 alkoxy selected from methoxy, ethoxy, propoxy or isopropoxy.   In one aspect of the use of a compound of Formula (I), R 6  is halo-C 1-8 alkoxy selected from trihalo-methoxy, dihalo-methoxy, halo-methoxy, trihalo-ethoxy, dihalo-ethoxy, halo-ethoxy, trihalo-propoxy, dihalo-propoxy or halo-propoxy; wherein, halo is selected from fluoro, chloro, bromo or iodo.   In one aspect of the use of a compound of Formula (I), R 7  is C 3-14 cycloalkyl, C 3-14 cycloalkyl-oxy, aryl, heterocyclyl or heteroaryl; wherein C 3-14 cycloalkyl is selected from cyclopropyl or cyclobutoxy; wherein aryl is selected from phenyl; wherein heterocyclyl is selected from oxetanyl, pyrrolidinyl or 1,2,3,6-tetrahydropyridinyl; and, wherein heteroaryl is selected from thienyl or pyridinyl.   In another aspect of the use of a compound of Formula (I), R 7  is C 3-14 cycloalkyl or C 3-14 cycloalkyl-oxy, wherein each instance of C 3-14 cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.   In another aspect of the use of a compound of Formula (I), R 7  is C 3-8 cycloalkyl or C 3-8 cycloalkyl-oxy, wherein each instance of C 3-8 cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.   In one aspect of the use of a compound of Formula (I), R 7  is aryl selected from phenyl.   In one aspect of the use of a compound of Formula (I), R 7  is heterocyclyl selected from oxetanyl, pyrrolidinyl or 1,2,3,6-tetrahydropyridinyl.   In another aspect of the use of a compound of Formula (I), R 7  is heterocyclyl selected from oxetan-3-yl, pyrrolidin-1-yl or 1,2,3,6-tetrahydropyridin-4-yl.   In one aspect of the use of a compound of Formula (I), R 7  is heteroaryl selected from thienyl or pyridinyl.   In another aspect of the use of a compound of Formula (I), R 7  is heteroaryl selected from pyridinyl.   In one aspect of the use of a compound of Formula (I), R 7  is heteroaryl selected from thien-2-yl or pyridin-2-yl.   In another aspect of the use of a compound of Formula (I), R 7  is heteroaryl selected from pyridin-2-yl.   In one aspect of the use of a compound of Formula (I), R c  is hydrogen or C 1-8 alkyl.   In another aspect of the use of a compound of Formula (I),   R 1  is heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl)(C 1-8 alkyl)amino, heterocyclyl-amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino, (heterocyclyl-C 1-8 alkyl) 2 -amino, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C 3-14 cycloalkyl, aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl) 2 -amino, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-C 1-8 alkoxy, heteroaryl-amino, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl) 2 -amino, (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl; wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with R 3  and R 4  substituents; and,   wherein, heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 3,6-dihydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazinyl, (8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazinyl, (8aS)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazinyl, (8aR)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazinyl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, (3aR,4aR,7aS)-hexahydro-1H-cyclobuta[1,2-c:1,4-c′]dipyrrol-(3H)-yl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,6-diazabicyclo[3.2.0]hept-3-yl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 4,7-diazaspiro[2.5]oct-7-yl, 2,6-diazaspiro[3.4]oct-2-yl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl or 6,9-diazaspiro[4.5]decyl.   In another aspect of the use of a compound of Formula (I),   R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino;   wherein, aryl is phenyl;   wherein, heterocyclyl is selected from 1,2,3,6-tetrahydropyridinyl, 1,3-benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl;   wherein, heteroaryl is selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl, quinazolinyl, quinoxalinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, pyrazolo[4,3-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-b]pyridazinyl, pyrido[1,2-a]pyrimidinyl or pyrido[1,2-a]pyrimidinone; and, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl)(C 1-8 alkyl)amino, heterocyclyl-amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino, (heterocyclyl-C 1-8 alkyl) 2 -amino, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C 3-14 cycloalkyl, aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl) 2 -amino, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-C 1-8 alkoxy, heteroaryl-amino, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl) 2 -amino, (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl;   wherein, heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 3,6-dihydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, 1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolyl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazinyl, (8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazinyl, (8aS)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazinyl, (8aR)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazinyl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, (3aR,4aR,7aS)-hexahydro-1H-cyclobuta[1,2-c:1,4-c′]dipyrrol-(3H)-yl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,6-diazabicyclo[3.2.0]heptyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 4,7-diazaspiro[2.5]octyl, 2,6-diazaspiro[3.4]octyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl or 6,9-diazaspiro[4.5]decyl; and, wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with R 3  and R 4  substituents; and   R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino;   wherein, heterocyclyl is selected from 1,2,3,6-tetrahydropyridin-4-yl, 1,3-benzodioxol-5-yl or 2,3-dihydro-1,4-benzodioxin-6-yl;   wherein, heteroaryl is selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl, quinazolinyl, quinoxalinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, pyrazolo[4,3-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, imidazo[1,2-a]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-b]pyridazinyl, pyrido[1,2-a]pyrimidinyl or pyrido[1,2-a]pyrimidinone; and, wherein, each instance of heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is C 1-8 alkyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, C 1-8 alkoxy-C 1-8 alkyl-amino, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, amino-C 1-8 alkyl-amino, (amino-C 1-8 alkyl) 2 -amino, (amino-C 1-8 alkyl)(C 1-8 alkyl)amino, C 1-8 alkyl-amino-C 1-8 alkyl-amino, (C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, amino-C 1-8 alkoxy, C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, amino-C 2-8 alkenyl, C 1-8 alkyl-amino-C 2-8 alkenyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkenyl, amino-C 2-8 alkynyl, C 1-8 alkyl-amino-C 2-8 alkynyl, (C 1-8 alkyl) 2 -amino-C 2-8 alkynyl, halo-C 1-8 alkyl-amino, (halo-C 1-8 alkyl) 2 -amino, (halo-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl, hydroxy-C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy, hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl-amino, [(hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino or [(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl](C 1-8 alkyl)amino; and R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl)(C 1-8 alkyl)amino, heterocyclyl-amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino, (heterocyclyl-C 1-8 alkyl) 2 -amino, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C 3-14 cycloalkyl, aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl) 2 -amino, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-C 1-8 alkoxy, heteroaryl-amino, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl) 2 -amino, (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl; wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with R 3  and R 4  substituents; and   R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl)(C 1-8 alkyl)amino, heterocyclyl-amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino, (heterocyclyl-C 1-8 alkyl) 2 -amino, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl or heterocyclyl-carbonyl-oxy; wherein, each instance of heterocyclyl is optionally substituted with R 3  and R 4  substituents; and R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with   R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I), R 1  is heterocyclyl optionally substituted with one, two or three R 3  substituents and optionally, with one additional R 4  substituents; or, optionally, with one, two, three or four R 3  substituents; and   R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is C 3-14 cycloalkyl optionally substituted with R 3  and R 4  substituents; and   R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl) 2 -amino, (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl; wherein, each instance of aryl is optionally substituted with R 3  and R 4  substituents; and R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is aryl-C 1-8 alkyl-amino optionally substituted with R 3  and R 4  substituents; and   R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-C 1-8 alkoxy, heteroaryl-amino, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl) 2 -amino, (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl or (heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl; wherein, each instance of heterocyclyl, C 3-14 cycloalkyl, aryl and heteroaryl is optionally substituted with R 3  and R 4  substituents; and   R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   In another aspect of the use of a compound of Formula (I),   R 1  is heteroaryl optionally substituted with R 3  and R 4  substituents; and   R 2  is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R 6  and R 7  substituents.   An aspect of the use of the compound of Formula (I) is the use of a compound selected from Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII) or Formula (XIV):   

     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
         
         or a form thereof. 
         In an aspect of the use of the compound of Formula (I), w 3  is C—R 1 , w 6  is C—R 2 , w 1 , w 4 , w 5  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (I), w 3  is C—R 2 , w 6  is C—R 1 , w 1 , w 4 , w 5  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (I), w 4  is C—R 1 , w 7  is C—R 2 , w 1 , w 3  and w 5  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N. 
         In another aspect of the use of the compound of Formula (I), w 4  is C—R 2 , w 7  is C—R 1 , w 1 , w 3  and w 5  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (II), w 3  is C—R 1 , w 6  is C—R 2 , w 4 , w 5  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (II), w 3  is C—R 2 , w 6  is C—R 1 , w 4 , w 5  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (II), w 4  is C—R 1 , w 7  is C—R 2 , w 3  and w 5  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N. 
         In another aspect of the use of the compound of Formula (II), w 4  is C—R 2 , w 7  is C—R 1 , w 3  and w 5  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (III), w 3  is C—R 1 , w 6  is C—R 2  and w 1 , w 4 , w 5  and w 7  are independently C—R a  or N. 
         In another aspect of the use of the compound of Formula (III), w 3  is C—R 2 , w 6  is C—R 1  and w 1 , w 4 , w 5  and w 7  are independently C—R a  or N. 
         In another aspect of the use of the compound of Formula (III), w 4  is C—R 1 , w 7  is C—R 2 , w 1 , w 3  and w 5  are independently C—R a  or N and w 6  is C—R e  or N. 
         In another aspect of the use of the compound of Formula (III), w 4  is C—R 2 , w 7  is C—R 1 , w 1 , w 3  and w 5  are independently C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (IV), w 4  is C—R 1 , w 7  is C—R 2 , w 1  and w 5  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N. 
         In another aspect of the use of the compound of Formula (IV), w 4  is C—R 2 , w 7  is C—R 1 , w 1  and w 5  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (V), w 3  is C—R 1 , w 6  is C—R 2 , w 1 , w 5  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (V), w 3  is C—R 2 , w 6  is C—R 1 , w 1 , w 5  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In an aspect of the use of the compound of Formula (VI), w 3  is C—R 1 , w 6  is C—R 2 , w 1 , w 4  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (VI), w 3  is C—R 2 , w 6  is C—R 1 , w 1 , w 4  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (VI), w 4  is C—R 1 , w 7  is C—R 2 , w 1  and w 3  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N. 
         In another aspect of the use of the compound of Formula (VI), w 4  is C—R 2 , w 7  is C—R 1 , w 1  and w 3  are independently C—R a  or N, w 2  is C—R b  or N and w 6  is C—R e  or N. 
         In another aspect of the use of the compound of Formula (VII), w 4  is C—R 1 , w 7  is C—R 2 , w 1 , w 3  and w 5  are C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (VII), w 4  is C—R 2 , w 7  is C—R 1 , w 1 , w 3  and w 5  are C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (VIII), w 3  is C—R 1 , w 6  is C—R 2 , w 1 , w 4  and w 5  are C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (VIII), w 3  is C—R 2 , w 6  is C—R 1 , w 1 , w 4  and w 5  are C—R a  or N and w 2  is C—R b  or N. 
         In an aspect of the use of the compound of Formula (IX), w 3  is C—R 1 , w 6  is C—R 2 , w 4  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (IX), w 3  is C—R 2 , w 6  is C—R 1 , w 4  and w 7  are independently C—R a  or N and w 2  is C—R b  or N. 
         In another aspect of the use of the compound of Formula (IX), w 4  is C—R 1 , w 7  is C—R 2 , w 2  is C—R b  or N, w 3  is C—R a  or N and w 6  is C—R e  or N. 
         In another aspect of the use of the compound of Formula (IX), w 4  is C—R 2 , w 7  is C—R 1 , w 2  is C—R b  or N, w 3  is C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (X), w 3  is C—R 1 , w 6  is C—R 2 , w 2  is C—R b  or N and w 5  and w 7  are independently C—R a  or N. 
         In another aspect of the use of the compound of Formula (X), w 3  is C—R 2 , w 6  is C—R 1 , w 2  is C—R b  or N and w 5  and w 7  are independently C—R a  or N. 
         In an aspect of the use of the compound of Formula (XI), w 4  is C—R 1 , w 7  is C—R 2 , w 2  is C—R b  or N, w 5  is C—R a  or N and w 6  is C—R e  or N. 
         In another aspect of the use of the compound of Formula (XI), w 4  is C—R 2 , w 7  is C—R 1 , w 2  is C—R b  or N, w 5  is C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (XII), w 3  is C—R 1 , w 6  is C—R 2  and w 4 , w 5  and w 7  are independently C—R a  or N. 
         In another aspect of the use of the compound of Formula (XII), w 3  is C—R 2 , w 6  is C—R 1  and w 4 , w 5  and w 7  are independently C—R a  or N. 
         In another aspect of the use of the compound of Formula (XII), w 4  is C—R 1 , w 7  is C—R 2 , w 3  and w 5  are independently C—R a  or N and w 6  is C—R e  or N. 
         In another aspect of the use of the compound of Formula (XII), w 4  is C—R 2 , w 7  is C—R 1 , w 3  and w 5  are independently C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (XIII), w 3  is C—R 1 , w 6  is C—R 2 , w 2  is C—R b  or N and w 4  and w 5  are independently C—R a  or N. 
         In another aspect of the use of the compound of Formula (XIII), w 3  is C—R 2 , w 6  is C—R 1 , w 2  is C—R b  or N and w 4  and w 5  are independently C—R a  or N. 
         In an aspect of the use of the compound of Formula (XIV), w 4  is C—R 1 , w 7  is C—R 2 , w 2  is C—R b  or N and w 3  and w 5  are independently C—R a  or N. 
         In another aspect of the use of the compound of Formula (XIV), w 4  is C—R 2 , w 7  is C—R 1 , w 2  is C—R b  or N and w 3  and w 5  are independently C—R a  or N. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound selected from Formula (II), Formula (III), Formula (IX), Formula (XI) or Formula (XII): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (II): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (III): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (IV): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (V): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (VI): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (VII): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (VIII): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (IX): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (X): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (XI): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the compound of Formula (I) is the use of the compound of Formula (XII): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (XIII): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (XIV): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII) or Formula (XIV) is the use of a compound selected from Formula (Ia), Formula (IIa), Formula (IIIa), Formula (IVa), Formula (Va), Formula (VIa), Formula (VIIa), Formula (VIIIa), Formula (IXa), Formula (Xa), Formula (XIa), Formula (XIIa), Formula (XIIIa) or Formula (XIVa), respectively: 
       
    
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
         
         or a form thereof. 
         In an aspect of the use of the compound of Formula (Ia), one of w 3 , w 4 , w 6  and w 7  is C—R 1  and one other of w 3 , w 4 , w 6  and w 7  is C—R 2 , provided that, 
         when w 3  is C—R 1 , then w 6  is C—R 2  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 3  is C—R 2 , then w 6  is C—R 1  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 4  is C—R 1 , then w 7  is C—R 2  and w 3  is C—R a  or N and w 6  is C—R e  or N; or, 
         when w 4  is C—R 2 , then w 7  is C—R 1  and w 3  is C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (IIa), one of w 3 , w 4 , w 6  and w 7  is C—R 1  and one other of w 3 , w 4 , w 6  and w 7  is C—R 2 , provided that, 
         when w 3  is C—R 1 , then w 6  is C—R 2  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 3  is C—R 2 , then w 6  is C—R 1  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 4  is C—R 1 , then w 7  is C—R 2  and w 3  is C—R a  or N and w 6  is C—R e  or N; or, 
         when w 4  is C—R 2 , then w 7  is C—R 1  and w 3  is C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (IIIa), one of w 3 , w 4 , w 6  and w 7  is C—R 1  and one other of w 3 , w 4 , w 6  and w 7  is C—R 2 , provided that, 
         when w 3  is C—R 1 , then w 6  is C—R 2  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 3  is C—R 2 , then w 6  is C—R 1  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 4  is C—R 1 , then w 7  is C—R 2  and w 3  is C—R a  or N and w 6  is C—R e  or N; or, 
         when w 4  is C—R 2 , then w 7  is C—R 1  and w 3  is C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (IVa), one of w 4  and w 7  is C—R 1  and the other is C—R 2 , provided that, when w 4  is C—R 1 , then w 7  is C—R 2 ; or, when w 4  is C—R 2 , then w 7  is C—R 1 . 
         In an aspect of the use of the compound of Formula (Va), one of w 3  and w 6  is C—R 1  and the other is C—R 2 , provided that, when w 3  is C—R 1 , then w 6  is C—R 2 ; or, when w 3  is C—R 2 , then w 6  is C—R 1 . 
         In an aspect of the use of the compound of Formula (VIa), one of w 3 , w 4 , w 6  and w 7  is C—R 1  and one other of w 3 , w 4 , w 6  and w 7  is C—R 2 , provided that, 
         when w 3  is C—R 1 , then w 6  is C—R 2  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 3  is C—R 2 , then w 6  is C—R 1  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 4  is C—R 1 , then w 7  is C—R 2  and w 3  is C—R a  or N and w 6  is C—R e  or N; or, 
         when w 4  is C—R 2 , then w 7  is C—R 1  and w 3  is C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (VIIa), one of w 4  and w 7  is C—R 1  and the other is C—R 2 , provided that, when w 4  is C—R 1 , then w 7  is C—R 2 ; or, when w 4  is C—R 2 , then w 7  is C—R 1 . 
         In an aspect of the use of the compound of Formula (VIIIa), one of w 3  and w 6  is C—R 1  and the other is C—R 2 , provided that, when w 3  is C—R 1 , then w 6  is C—R 2 ; or, when w 3  is C—R 2 , then w 6  is C—R 1 . 
         In an aspect of the use of the compound of Formula (IXa), one of w 3 , w 4 , w 6  and w 7  is C—R 1  and one other of w 3 , w 4 , w 6  and w 7  is C—R 2 , provided that, 
         when w 3  is C—R 1 , then w 6  is C—R 2  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 3  is C—R 2 , then w 6  is C—R 1  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 4  is C—R 1 , then w 7  is C—R 2  and w 3  is C—R a  or N and w 6  is C—R e  or N; or, 
         when w 4  is C—R 2 , then w 7  is C—R 1  and w 3  is C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (Xa), one of w 3  and w 6  is C—R 1  and the other is C—R 2 , provided that, when w 3  is C—R 1 , then w 6  is C—R 2 ; or, when w 3  is C—R 2 , then w 6  is C—R 1 . 
         In an aspect of the use of the compound of Formula (XIa), one of w 4  and w 7  is C—R 1  and the other is C—R 2 , provided that, when w 4  is C—R 1 , then w 7  is C—R 2 ; or, when w 4  is C—R 2 , then w 7  is C—R 1 . 
         In an aspect of the use of the compound of Formula (XIIa), one of w 3 , w 4 , w 6  and w 7  is C—R 1  and one other of w 3 , w 4 , w 6  and w 7  is C—R 2 , provided that, 
         when w 3  is C—R 1 , then w 6  is C—R 2  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 3  is C—R 2 , then w 6  is C—R 1  and w 4  and w 7  are independently C—R a  or N; or, 
         when w 4  is C—R 1 , then w 7  is C—R 2  and w 3  is C—R a  or N and w 6  is C—R e  or N; or, 
         when w 4  is C—R 2 , then w 7  is C—R 1  and w 3  is C—R a  or N and w 6  is C—R e  or N. 
         In an aspect of the use of the compound of Formula (XIIIa), one of w 3  and w 6  is C—R 1  and the other is C—R 2 , provided that, when w 3  is C—R 1 , then w 6  is C—R 2 ; or, when w 3  is C—R 2 , then w 6  is C—R 1 . 
         In an aspect of the use of the compound of Formula (XIVa), one of w 4  and w 7  is C—R 1  and the other is C—R 2 , provided that, when w 4  is C—R 1 , then w 7  is C—R 2 ; or, when w 4  is C—R 2 , then w 7  is C—R 1 . 
         An aspect of the use of the compound of Formula (I), Formula (II), Formula (III), Formula (IX), Formula (XI) or Formula (XII) is the use of the compound selected from Formula (Ia), Formula (IIa), Formula (IIIa), Formula (IXa), Formula (XIa) or Formula (XIIa), respectively: 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (I) is the use of the compound of Formula (Ia): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (II) is the use of the compound of Formula (IIa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (III) is the use of the compound of Formula (IIIa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (IV) is the use of the compound of Formula (IVa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (V) is the use of the compound of Formula (Va): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (VI) is the use of the compound of Formula (VIa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (VII) is the use of the compound of Formula (VIIa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (VIII) is the use of the compound of Formula (VIIIa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (IX) is the use of the compound of Formula (IXa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (X) is the use of the compound of Formula (Xa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (XI) is the use of the compound of Formula (XIa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (XII) is the use of the compound of Formula (XIIa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (XIII) is the use of the compound of Formula (XIIIa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         Another aspect of the use of the compound of Formula (XIV) is the use of the compound of Formula (XIVa): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Ia) is the use of a compound of Formula (Ia1), Formula (Ia2), Formula (Ia3) or Formula (Ia4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIa) is the use of a compound of Formula (IIa1), Formula (IIa2), Formula (IIa3) or Formula (IIa4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIIa) is the use of a compound of Formula (IIIa1), Formula (IIIa2), Formula (IIIa3) or Formula (IIIa4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IVa) is the use of a compound of Formula (IVa1) or Formula (IVa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Va) is the use of a compound of Formula (Va1) or Formula (Va2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIa) is the use of a compound of Formula (VIa1), Formula (VIa2), Formula (VIa3) or Formula (VIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIIa) is the use of a compound of Formula (VIIa1) or Formula (VIIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIIIa) is the use of a compound of Formula (VIIIa1) or Formula (VIIIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IXa) is the use of a compound of Formula (IXa1), Formula (IXa2), Formula (IXa3) or Formula (IXa4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Xa) is the use of a compound of Formula (Xa1) or Formula (Xa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIa) is the use of a compound of Formula (XIa1) or Formula (XIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIIa) is the use of a compound of Formula (XIIa1), Formula (XIIa2), Formula (XIIa3) or Formula (XIIa4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIIIa) is the use of a compound of Formula (XIIIa1) or Formula (XIIIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIVa) is the use of a compound of Formula (XIVa1) or Formula (XIVa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Ia) is the use of the compound of Formula (Ia1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Ia) is the use of the compound of Formula (Ia2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Ia) is the use of the compound of Formula (Ia3): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Ia) is the use of the compound of Formula (Ia4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIa) is the use of the compound of Formula (IIa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIa) is the use of the compound of Formula (IIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIa) is the use of the compound of Formula (IIa3): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIa) is the use of the compound of Formula (IIa4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIIa) is the use of the compound of Formula (IIIa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIIa) is the use of the compound of Formula (IIIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIIa) is the use of the compound of Formula (IIIa3): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IIIa) is the use of the compound of Formula (IIIa4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IVa) is the use of the compound of Formula (IVa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IVa) is the use of the compound of Formula (IVa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Va) is the use of the compound of Formula (Va1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Va) is the use of the compound of Formula (Va2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIa) is the use of the compound of Formula (VIa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIa) is the use of the compound of Formula (VIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIa) is the use of the compound of Formula Formula (VIa3): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIa) is the use of the compound of Formula (VIa4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIIa) is the use of the compound of Formula (VIIa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIIa) is the use of the compound of Formula (VIIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIIIa) is the use of the compound of Formula (VIIIa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (VIIIa) is the use of the compound of Formula (VIIIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IXa) is the use of the compound of Formula (IXa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IXa) is the use of the compound of Formula (IXa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IXa) is the use of the compound of Formula (IXa3): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (IXa) is the use of the compound of Formula (IXa4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Xa) is the use of the compound of Formula (Xa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (Xa) is the use of the compound of Formula (Xa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIa) is the use of the compound of Formula (XIa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIa) is the use of the compound of Formula (XIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIIa) is the use of the compound of Formula (XIIa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIIa) is the use of the compound of Formula (XIIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIIa) is the use of the compound of Formula (XIIa3): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIIa) is the use of the compound of Formula (XIIa4): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIIIa) is the use of the compound of Formula (XIIIa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIIIa) is the use of the compound of Formula (XIIIa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIVa) is the use of the compound of Formula (XIVa1): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (XIVa) is the use of the compound of Formula (XIVa2): 
       
    
     
       
         
         
             
             
         
       
         
         or a form thereof. 
         An aspect of the use of the compound of Formula (I) or a form thereof is a compound selected from the group consisting of: 
       
    
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
wherein the form of the compound is selected from the group consisting of a salt, prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
     An aspect of the use of the compound of Formula (I) or a form thereof is a compound selected from the group consisting of (where compound number (# 1 ) indicates that a salt form of the compound was isolated):   

                                 Cpd   Name                   1   2-(4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        2   2-(4-methoxyphenyl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        3   2-(4-methoxyphenyl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        4   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-           one        5   7-(1,4-diazepan-1-yl)-2-(4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one        6   2-(3,4-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        7   2-(3,4-dimethoxyphenyl)-7-(3,3-dimethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        8   2-(3,4-dimethoxyphenyl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        9   2-(3,4-dimethoxyphenyl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        10   7-(1,4-diazepan-1-yl)-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one        11   2-(3,4-dimethoxyphenyl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        12   2-(4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        13   2-(3,4-dimethoxyphenyl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        14   2-(3,4-dimethoxyphenyl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-           4-one        15   2-(3,4-dimethoxyphenyl)-7-(4-propylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        16   2-(4-methoxyphenyl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        17   7-(3,3-dimethylpiperazin-1-yl)-2-(4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one        18   2-(1,3-benzodioxol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        19   2-(1,3-benzodioxol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        20   2-(1,3-benzodioxol-5-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        21   2-(1,3-benzodioxol-5-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-           4-one        22   2-(3-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        23   2-(3-methoxyphenyl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        24   2-(3-methoxyphenyl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        25   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(3-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-           one        26   7-(4-ethylpiperazin-1-yl)-2-(3-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one        27   7-(1,4-diazepan-1-yl)-2-(3-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one        28   2-(3-methoxyphenyl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        29   2-(6-methylimidazo[1,2-a]pyridin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        30   2-(3,4-dimethoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        31   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        32   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        33   2-phenyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        34   7-[(3S)-3-methylpiperazin-1-yl]-2-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one        35   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        36   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-(3,3-dimethylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one        37   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        38   7-(1,4-diazepan-1-yl)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        39   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one        40   2-(3,4-dimethoxyphenyl)-9-fluoro-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one        41   2-(3-chlorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        42   2-(4-chlorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        43   7-(piperazin-1-yl)-2-[3-(trifluoromethyl)phenyl]-4H-pyrido[1,2-a]pyrimidin-4-one        44   7-(piperazin-1-yl)-2-[4-(trifluoromethyl)phenyl]-4H-pyrido[1,2-a]pyrimidin-4-one        45   2-(3-methylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        46   2-(4-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        47   2-(4-nitrophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        48   2-(3,4-dimethoxyphenyl)-9-fluoro-7-(piperidin-4-ylamino)-4H-pyrido[1,2-a]pyrimidin-4-one        49   2-[4-(dimethylamino)phenyl]-9-fluoro-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        50   2-[4-(dimethylamino)phenyl]-9-fluoro-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        51   2-(2-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        52   3-(3,4-dimethoxyphenyl)-8-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        53   2-[4-(dimethylamino)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        54   2-[4-(dimethylamino)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one        55   2-(3,4-dimethylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        56   2-(3,4-dimethylphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        57   2-[3-(dimethylamino)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        58   2-[3-(dimethylamino)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one        59   2-[4-(difluoromethoxy)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        60   2-[4-(difluoromethoxy)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one        61   2-(3-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        62   2-(3-nitrophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        63   2-(4-methylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        64   2-(2-fluoro-4,5-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        65   2-(2-fluoro-4,5-dimethoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        66   7-(3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-           one        67   2-[4-methoxy-3-(trifluoromethyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        68   2-[4-methoxy-3-(trifluoromethyl)phenyl]-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        69   2-[4-methoxy-3-(trifluoromethyl)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        70   2-(3,4-dimethoxyphenyl)-9-methoxy-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one           71 1     2-(3,5-difluoro-4-hydroxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        72   2-(3-fluoro-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        73   4-[4-oxo-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-2-yl]benzonitrile        74   2-(6-methylimidazo[1,2-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        75   2-(6-methylimidazo[1,2-a]pyrazin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        76   2-[3-fluoro-5-(trifluoromethyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        77   2-[4-fluoro-3-(trifluoromethyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        78   2-[2-methoxy-3-(trifluoromethyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        79   2-(3,5-difluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        80   7-(piperazin-1-yl)-2-[3-(trifluoromethoxy)phenyl]-4H-pyrido[1,2-a]pyrimidin-4-one        81   2-[4-methoxy-3-(trifluoromethoxy)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one        82   2-[4-hydroxy-3-(trifluoromethoxy)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one        83   2-[4-methoxy-3-(trifluoromethoxy)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        84   2-[4-hydroxy-3-(trifluoromethoxy)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one        85   2-(3,4-dimethoxyphenyl)-4-oxo-7-(piperazin-1-yl)-4H-quinolizine-1-carbonitrile        86   2-(3-fluoro-4-methoxyphenyl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one        87   2-(3-fluoro-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one        88   2-(6-methoxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        89   2-(2,4-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        90   2-(2,4-dimethoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        91   2-(3,4-dimethoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-quinolizin-4-one        92   2-(5-fluoropyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        93   2-(5-fluoropyridin-3-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        94   2-(5-chloropyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        95   2-(5-chloropyridin-3-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one        96   2-(5-chloro-6-methoxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        97   2-(1H-indol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        98   2-(1H-indol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one        99   2-[3-(difluoromethoxy)-4-methoxyphenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       100   2-[3-(difluoromethoxy)-4-hydroxyphenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       101   2-[3-(difluoromethoxy)-4-methoxyphenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       102   2-[3-(difluoromethoxy)-4-hydroxyphenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       103   2-(3-fluoro-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-quinolizin-4-one       104   2-(3-fluoro-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-quinolizin-4-one       105   2-(3,5-difluorophenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       106   2-(3,4-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-quinolizin-4-one       107   2-(imidazo[1,2-a]pyridin-7-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       108   2-(imidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       109   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       110   2-(3-chloro-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       111   2-(3-chloro-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       112   2-(3-ethoxy-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       113   2-(3-ethoxy-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       114   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       115   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       116   7-(1,4-diazepan-1-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       117   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       118   2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       119   2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       120   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       121   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       122   2-(3,4-dimethoxyphenyl)-7-(2-methylpyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       123   7-(piperazin-1-yl)-2-[2-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       124   2-(2-ethylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       125   2-(2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       126   2-(3,4-dimethoxyphenyl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       127   7-(4-aminopiperidin-1-yl)-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one       128   7-(piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       129   2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       130   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       131   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       132   7-(1,4-diazepan-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       133   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       134   2-(2-methyl-1,3-benzoxazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       135   2-(2-methyl-1,3-benzothiazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       136   2-(2-methyl-1,3-benzothiazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       137   2-(2-methyl-2H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       138   2-(2-methyl-2H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       139   2-(3-fluoro-5-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       140   2-(3-fluoro-5-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       141   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       142   2-(3,4-dimethoxyphenyl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       143   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       144   2-(3,4-dimethoxyphenyl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       145   2-(3-fluoro-4,5-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       146   2-(3,4-dimethoxyphenyl)-7-(4-hydroxypiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       147   2-(3,4-dimethoxyphenyl)-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       148   2-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       149   2-(4-methoxy-3-methylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       150   3-[4-oxo-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-2-yl]benzonitrile       151   2-methoxy-5-[4-oxo-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-2-yl]benzonitrile       152   2-(3-fluoro-4-hydroxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       153   2-(4-ethoxy-3-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       154   2-[3-fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       155   2-(2-methyl-1,3-benzoxazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       156   2-(2-methyl-1,3-benzoxazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       157   2-(3-fluoro-4-methylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       158   2-(3-fluoro-4-methylphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       159   7-[(3S)-3-aminopyrrolidin-1-yl]-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one       160   2-(3,4-dimethoxyphenyl)-9-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       161   7-(1,4-diazepan-1-yl)-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       162   7-[(3S)-3-methylpiperazin-1-yl]-2-(4-methyl-1,3-thiazol-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       163   2-(4-methyl-1,3-thiazol-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       164   2-(3,4-dimethoxyphenyl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       165   2-(3,4-dimethoxyphenyl)-7-[(3S)-3-(propan-2-ylamino)pyrrolidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       166   2-(3-fluoro-4-methoxyphenyl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       167   2-(4-methoxy-3-nitrophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       168   2-[3-fluoro-4-(methylsulfanyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       169   7-(4-methyl-1,4-diazepan-1-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       170   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       171   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       172   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       173   2-(5-fluoro-6-methoxypyridin-3-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       174   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(5-fluoro-6-methoxypyridin-3-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       175   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       176   2-(2-methyl-1,3-benzothiazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       177   2-(2-methyl-1,3-benzothiazol-5-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       178   7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       179   2-(4-methyl-1H-imidazol-1-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       180   2-(4-methyl-1H-imidazol-1-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       181   2-(3,4-dimethoxyphenyl)-7-{[2-(methylamino)ethyl]amino}-4H-pyrido[1,2-a]pyrimidin-4-one       182   2-(5-fluoro-6-methoxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       183   2-(3,5-difluoro-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       184   2-(3,5-difluoro-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       185   7-[4-(dimethylamino)piperidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-           a]pyrimidin-4-one       186   2-(3-fluoro-4-methoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       187   2-(3,4-dimethoxyphenyl)-7-(piperidin-4-ylamino)-4H-pyrido[1,2-a]pyrimidin-4-one       188   2-(3,4-dimethoxyphenyl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       189   2-(3-chloro-5-fluorophenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       190   2-(3-chloro-5-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       191   7-[(3S)-3-methylpiperazin-1-yl]-2-(1-methyl-1H-pyrazol-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       192   2-(1-methyl-1H-pyrazol-4-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       193   2-(2-methyl-1,3-benzoxazol-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       194   7-(3,3-dimethylpiperazin-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       195   7-(1,4-diazepan-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       196   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       197   7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       198   7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       199   2-(4,5-dimethoxypyridin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       200   7-[3-(dimethylamino)pyrrolidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-quinolizin-4-one       201   7-(4-aminopiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)-4H-quinobzin-4-one       202   7-(4-ethylpiperazin-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one           203 1     7-[4-(dimethylamino)piperidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-quinolizin-4-one       204   2-(3-fluoro-4-methoxyphenyl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       205   7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-           a]pyrimidin-4-one       206   7-[(3R,4R)-3-(dimethylamino)-4-hydroxypyrrobdin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-           pyrido[1,2-a]pyrimidin-4-one       207   7-(4-aminopiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one       208   2-(3-fluoro-4-methoxyphenyl)-7-[4-(methylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-           4-one       209   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       210   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       211   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       212   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       213   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       214   2-(3,4-dimethoxyphenyl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       215   2-(4-fluoro-3-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       216   2-(4-fluoro-3-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       217   2-(3,4-difluoro-5-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       218   2-(3,4-difluoro-5-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       219   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       220   7-(3-fluoro-4-methoxyphenyl)-2-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       221   2-(2-methyl-1,3-benzothiazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       222   2-(3-fluoro-4-methoxyphenyl)-7-[(3S)-3-(methylamino)pyrrolidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       223   2-(3-fluoro-4-methoxyphenyl)-7-{4-[(methylamino)methyl]piperidin-1-yl}-4H-pyrido[1,2-           a]pyrimidin-4-one       224   7-[(3S)-3-aminopyrrolidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-           one       225   2-(3-fluoro-4-methoxyphenyl)-7-{[(3R)-1-methylpyrrolidin-3-yl]amino}-4H-pyrido[1,2-           a]pyrimidin-4-one       226   7-{4-[(dimethylamino)methyl]piperidin-1-yl}-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-           a]pyrimidin-4-one       227   2-(6-methoxypyridin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       228   7-(piperazin-1-yl)-2-(pyridin-3-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       229   2-(5-methoxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       230   3-fluoro-5-{7-[(3S)-3-methylpiperazin-1-yl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-           yl}benzonitrile       231   3-fluoro-5-[4-oxo-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-2-yl]benzonitrile       232   2-(3-fluoro-4-methoxyphenyl)-7-[(3′S,4′S)-4′-hydroxy-1,3′-bipyrrolidin-1′-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       233   2-(3-fluoro-4-methoxyphenyl)-7-{methyl[(3R)-pyrrolidin-3-yl]amino}-4H-pyrido[1,2-           a]pyrimidin-4-one       234   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       235   2-(3,4-dimethoxyphenyl)-7-[(1-methylpiperidin-4-yl)oxy]-4H-pyrido[1,2-a]pyrimidin-4-one       236   2-(3,4-dimethoxyphenyl)-7-[(3S)-pyrrolidin-3-yloxy]-4H-pyrido[1,2-a]pyrimidin-4-one       237   2-(3,4-dimethoxyphenyl)-7-(piperidin-4-yloxy)-4H-pyrido[1,2-a]pyrimidin-4-one       238   7-(1,4-diazepan-1-yl)-2-(3,4-dimethoxyphenyl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one       239   2-(3-fluoro-4-methoxyphenyl)-7-{methyl[(3R)-1-methylpyrrolidin-3-yl]amino}-4H-           pyrido[1,2-a]pyrimidin-4-one       240   7-[4-(dimethylamino)piperidin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       241   7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       242   7-(4-aminopiperidin-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       243   7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       244   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       245   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-quinolizin-4-one       246   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aR)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       247   2-(3,4-dimethoxyphenyl)-9-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       248   2-(3,4-dimethoxyphenyl)-7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       249   2-(3,4-dimethoxyphenyl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-quinolizin-4-one       250   2-(3,4-dimethoxyphenyl)-9-methyl-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       251   2-(3,4-dimethoxyphenyl)-9-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       252   2-(3,4-dimethoxyphenyl)-9-methyl-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       253   7-(1,4-diazepan-1-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       254   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       255   7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       256   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       257   2-(3,4-dimethoxyphenyl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-9-methyl-           4H-pyrido[1,2-a]pyrimidin-4-one       258   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       259   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       260   2-(3,4-dimethoxyphenyl)-9-methyl-7-[(3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       261   2-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)piperidin-1-yl]-9-methyl-4H-pyrido[1,2-           a]pyrimidin-4-one       262   7-[(1R,5S)-8-azabicyclo[3.2.1]oct-2-en-3-yl]-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-           a]pyrimidin-4-one       263   2-(3,4-dimethoxyphenyl)-7-(1,2,5,6-tetrahydropyridin-3-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       264   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       265   2-(2-ethyl-1,3-benzoxazol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       266   2-(2-ethyl-1,3-benzoxazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-           4-one       267   2-(2-methyl-1,3-benzoxazol-6-yl)-7-[(3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       268   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       269   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       270   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       271   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       272   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       273   7-(4-aminopiperidin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       274   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       275   7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       276   2-(4-aminopiperidin-1-yl)-7-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one       277   2-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-7-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-           a]pyrimidin-4-one       278   2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-7-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-           a]pyrimidin-4-one       279   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aS)-5-(2-hydroxyethyl)hexahydropyrrolo[3,4-           c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       280   2-(3-fluoro-4-methoxyphenyl)-7-[(3aS,6aS)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       281   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aS)-5-(propan-2-yl)hexahydropyrrolo[3,4-c]pyrrol-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       282   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-           a]pyrimidin-4-one       283   7-(3,3-dimethylpiperazin-1-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       284   7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       285   7-[4-(dimethylamino)piperidin-1-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       286   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperidin-4-yloxy)-4H-pyrido[1,2-a]pyrimidin-4-one       287   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       288   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       289   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       290   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       291   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       292   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       293   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       294   7-(3-fluoro-4-methoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       295   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       296   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       297   7-[4-(dimethylamino)piperidin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       298   2-[4-(dimethylamino)piperidin-1-yl]-7-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-           a]pyrimidin-4-one       299   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       300   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       301   2-(3-fluoro-4-methoxyphenyl)-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       302   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       303   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       304   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       305   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       306   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       307   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       308   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       309   7-(4-ethylpiperazin-1-yl)-2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       310   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(4-propylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       311   7-[(3aR,6aS)-5-ethylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-(3-fluoro-4-methoxyphenyl)-           4H-pyrido[1,2-a]pyrimidin-4-one       312   2-(3-fluoro-4-methoxyphenyl)-9-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       313   2-(3-fluoro-4-methoxyphenyl)-7-[(4aR,7aR)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       314   2-(3,4-dimethoxyphenyl)-9-methyl-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       315   2-(3-fluoro-4-methoxyphenyl)-9-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       316   7-(3-fluoro-4-methoxyphenyl)-2-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       317   7-(3-fluoro-4-methoxyphenyl)-2-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       318   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       319   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       320   2-(3,4-dimethoxyphenyl)-7-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       321   2-(3,4-dimethoxyphenyl)-7-[(2R)-2-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       322   2-(2-methyl-1,3-benzoxazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-quinolizin-4-one       323   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-quinolizin-4-one       324   7-[(3S)-4-ethyl-3-methylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-quinolizin-4-           one       325   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-quinobzin-4-one       326   7-(4-aminopiperidin-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-quinolizin-4-one       327   2-(3-fluoro-4-methoxyphenyl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       328   7-[4-(dimethylamino)piperidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-9-methyl-4H-pyrido[1,2-           a]pyrimidin-4-one       329   2-(3-fluoro-4-methoxyphenyl)-9-methyl-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       330   7-[4-(cyclopropylamino)piperidin-1-yl]-2-(3,4-dimethoxyphenyl)-9-methyl-4H-pyrido[1,2-           a]pyrimidin-4-one       331   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3,4-dimethylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       332   2-(3,4-dimethoxyphenyl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-9-methyl-4H-pyrido[1,2-           a]pyrimidin-4-one       333   2-(3,4-dimethoxyphenyl)-7-[(3R)-3,4-dimethylpiperazin-1-yl]-9-methyl-4H-pyrido[1,2-           a]pyrimidin-4-one       334   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       335   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       336   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       337   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       338   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       339   7-[4-(dimethylamino)piperidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       340   7-(3,3-dimethylpiperazin-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       341   7-(4-cyclopropylpiperazin-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       342   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       343   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       344   2-(3,4-dimethoxyphenyl)-9-methyl-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       345   2-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)piperidin-1-yl]-9-ethyl-4H-pyrido[1,2-           a]pyrimidin-4-one       346   2-(3,4-dimethoxyphenyl)-7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       347   7-[4-(dimethylamino)piperidin-1-yl]-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       348   7-(4-aminopiperidin-1-yl)-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       349   7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-(2-methyl-1,3-benzothiazol-5-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       350   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       351   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       352   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       353   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrimido[1,2-a]pyrimidin-4-           one       354   7-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       355   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       356   7-(1-cyclobutyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       357   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       358   2-(3,4-dimethoxyphenyl)-9-methyl-7-[4-(methylamino)piperidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       359   2-(3,4-dimethoxyphenyl)-7-[4-(ethylamino)piperidin-1-yl]-9-methyl-4H-pyrido[1,2-           a]pyrimidin-4-one       360   2-(3,4-dimethoxyphenyl)-8-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       361   2-(3,4-dimethoxyphenyl)-7-[4-(propan-2-ylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-           4-one       362   7-(1-cyclobutyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-           a]pyrimidin-4-one       363   2-(3,4-dimethoxyphenyl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       364   2-(3,4-dimethoxyphenyl)-7-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       365   2-(3,4-dimethoxyphenyl)-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       366   2-(3,4-dimethoxyphenyl)-7-[4-(methylamino)cyclohex-1-en-1-yl]-4H-pyrido[1,2-a]pyrimidin-           4-one       367   2-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)cyclohex-1-en-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       368   2-(3,4-dimethoxyphenyl)-7-{4-[ethyl(methyl)amino]cyclohex-1-en-1-yl}-4H-pyrido[1,2-           a]pyrimidin-4-one       369   2-(3,4-dimethoxyphenyl)-7-{4-[methyl(propyl)amino]cyclohex-1-en-1-yl}-4H-pyrido[1,2-           a]pyrimidin-4-one       370   2-(3,4-dimethoxyphenyl)-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       371   7-(3,4-dimethoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       372   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       373   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(propan-2-yl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       374   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(propan-2-yl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       375   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       376   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       377   7-(3,4-dimethoxyphenyl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       378   2-(3,4-dimethoxyphenyl)-9-methyl-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       379   7-(1-cyclobutyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(3,4-dimethoxyphenyl)-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one           380 1     2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one       381   7-(4-aminopiperidin-1-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       382   7-(3-aminopyrrolidin-1-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       383   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       384   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       385   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(2-methoxyethyl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       386   2-(3,4-dimethoxyphenyl)-9-methyl-7-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       387   2-(3,4-dimethoxyphenyl)-9-methyl-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       388   2-(3,4-dimethoxyphenyl)-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-9-methyl-4H-pyrido[1,2-           a]pyrimidin-4-one       389   2-(3,4-dimethoxyphenyl)-8-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       390   7-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(3,4-dimethoxyphenyl)-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       391   2-(3,4-dimethoxyphenyl)-8-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       392   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       393   7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       394   2-(2-methyl-1,3-benzothiazol-6-yl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       395   7-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       396   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       397   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       398   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-           one       399   7-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       400   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-           2-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       401   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       402   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-           one       403   2-(3-fluoro-4-methoxyphenyl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       404   2-(3,4-dimethoxyphenyl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       405   2-(3,4-dimethoxyphenyl)-7-[cis-4-(methylamino)cyclohexyl]-4H-pyrido[1,2-a]pyrimidin-4-           one       406   2-(3,4-dimethoxyphenyl)-7-(piperidin-3-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       407   2-(3,4-dimethoxyphenyl)-9-methyl-7-[4-(propylarnino)piperidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       408   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       409   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       410   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       411   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       412   7-(4-cyclopropylpiperazin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           413 1     2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one       414   2-(3,4-dimethoxyphenyl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       415   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       416   2-(3,4-dimethoxyphenyl)-9-methyl-7-[4-(propan-2-ylamino)piperidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       417   2-(3,4-dimethoxyphenyl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       418   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       419   2-(3,4-dimethoxyphenyl)-9-methyl-7-[4-(morpholin-4-yl)piperidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       420   2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       421   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one hydrochloride(1:1)       422   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one       423   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       424   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       425   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(pyrrolidin-1-yl)piperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       426   7-(1,4′-bipiperidin-1′-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       427   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       428   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(morpholin-4-yl)piperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       429   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       430   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       431   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       432   7-[4-(dimethylamino)piperidin-1-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       433   2-(3,4-dimethoxyphenyl)-7-{4-[(2-hydroxyethyl)amino]piperidin-1-yl}-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       434   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       435   7-[4-(diethylamino)piperidin-1-yl]-2-(3,4-dimethoxyphenyl)-9-methyl-4H-pyrido[1,2-           a]pyrimidin-4-one       436   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       437   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(pyrrolidin-1-yl)piperidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       438   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       439   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       440   7-(4-methylpiperazin-1-yl)-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       441   7-[(3S)-3-methylpiperazin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       442   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       443   2-(1-methyl-1H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       444   2-[6-(dimethylamino)pyridin-3-yl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       445   7-[4-(diethylamino)piperidin-1-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       446   2-(3,4-dimethoxyphenyl)-7-{4-[(2-hydroxyethyl)(methyl)amino]piperidin-1-yl}-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       447   2-(3,4-dimethoxyphenyl)-9-ethyl-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-           4-one       448   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       449   2-(1-methyl-1H-indazol-5-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       450   2-[6-(dimethylamino)pyridin-3-yl]-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       451   7-[4-(diethylamino)piperidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       452   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       453   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       454   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       455   2-(3,4-dimethoxyphenyl)-9-ethyl-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       456   2-(3,4-dimethoxyphenyl)-7-{4-[(2-methoxyethyl)amino]piperidin-1-yl}-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       457   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(4-methylpiperazin-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       458   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-           yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one       459   7-[4-(dimethylamino)piperidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-           4H-pyrido[1,2-a]pyrimidin-4-one       460   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       461   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       462   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       463   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       464   2-(1-methyl-1H-indazol-5-yl)-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       465   2-[6-(dimethylamino)pyridin-3-yl]-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       466   7-(4-ethylpiperazin-1-yl)-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       467   7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       468   7-[4-(dimethylamino)piperidin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       469   7-[4-(2-hydroxyethyl)piperazin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       470   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-propylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       471   7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-2-(1-methyl-1H-indazol-5-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       472   7-[(3R)-3-methylpiperazin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       473   2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       474   2-(2-methyl-2H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       475   2-(1-methyl-1H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       476   2-(2-methyl-2H-indazol-5-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       477   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       478   7-(1-ethylpiperidin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       479   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-           4H-pyrazino[1,2-a]pyrimidin-4-one       480   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       481   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-           4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       482   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-9-           methyl-4H-pyrido[1,2-a]pyrimidin-4-one       483   7-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-           9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one       484   2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       485   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       486   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       487   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       488   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       489   2-(1-methyl-1H-indazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       490   2-(1-methyl-1H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       491   7-[4-(dimethylamino)piperidin-1-yl]-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       492   7-(4-methyl-1,4-diazepan-1-yl)-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       493   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrimido[1,2-           b]pyridazin-4-one       494   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       495   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       496   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-ethyl-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       497   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methyl-4-(propan-2-yl)piperazin-           1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       498   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methyl-4-(propan-2-yl)piperazin-           1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       499   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one       500   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-           one       501   7-(1-ethylpiperidin-4-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrimido[1,2-b]pyridazin-4-           one       502   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-           4-one       503   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       504   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       505   2-(1-methyl-1H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-           4-one       506   2-(1-methyl-1H-indazol-5-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       507   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(1-methyl-1H-indazol-5-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       508   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-ethylpiperazin-1-yl)-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       509   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3R)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       510   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-           4H-pyrido[1,2-a]pyrimidin-4-one       511   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-9-           methyl-4H-pyrido[1,2-a]pyrimidin-4-one       512   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-           4-one       513   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrimido[1,2-           b]pyridazin-4-one       514   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrimido[1,2-           b]pyridazin-4-one       515   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       516   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       517   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       518   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       519   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       520   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(4-methyl-1,4-diazepan-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       521   2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one       522   2-(2-methyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one       523   7-(1-ethylpiperidin-4-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrimido[1,2-b]pyridazin-4-one       524   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrimido[1,2-           b]pyridazin-4-one       525   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrimido[1,2-           b]pyridazin-4-one       526   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-           pyrimido[1,2-b]pyridazin-4-one       527   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       528   7-[4-(dimethylamino)piperidin-1-yl]-2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       529   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       530   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       531   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       532   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(2-hydroxyethyl)-3-methylpiperazin-1-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       533   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-methoxyethyl)-3-           methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       534   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-{(3S)-4-[2-(2-hydroxyethoxy)ethyl]-3-           methylpiperazin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one       535   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-cyclopropyl-3-methylpiperazin-1-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       536   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-cyclobutyl-3-methylpiperazin-1-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       537   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-hydroxyethyl)-3-           methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       538   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-methoxyethyl)-3-           methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       539   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-hydroxyethyl)-3-           methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       540   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-{(3S)-4-[2-(2-hydroxyethoxy)ethyl]-3-           methylpiperazin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one       541   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methyl-4-(propan-2-yl)piperazin-1-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       542   7-[(3S)-4-cyclopropyl-3-methylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-           yl)-4H-pyrido[1,2-a]pyrimidin-4-one       543   7-[(3S)-4-cyclobutyl-3-methylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-           yl)-4H-pyrido[1,2-a]pyrimidin-4-one       544   7-(3,3-dimethylpiperazin-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       545   2-(1-methyl-1H-indazol-5-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       546   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       547   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       548   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       549   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       550   7-[4-(dimethylamino)piperidin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       551   7-[4-(diethylamino)piperidin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       552   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       553   2-(1-methyl-1H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       554   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       555   2-(2-methylimidazo[1,2-a]pyridin-7-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       556   2-(2-methylimidazo[1,2-a]pyridin-7-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       557   2-(2-methylimidazo[1,2-a]pyridin-7-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       558   7-(4-ethylpiperazin-1-yl)-2-(2-methylimidazo[1,2-a]pyridin-7-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       559   2-(2-methylimidazo[1,2-a]pyridin-7-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       560   7-(1-ethylpiperidin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-7-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       561   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       562   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-           methyl-4H-pyrido[1,2-a]pyrimidin-4-one       563   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-           4H-pyrido[1,2-a]pyrimidin-4-one       564   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3R,5S)-3,4,5-trimethylpiperazin-1-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       565   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-           4H-pyrido[1,2-a]pyrimidin-4-one       566   2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one       567   2-(2-methyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one       568   7-(1-ethylpiperidin-4-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one       569   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       570   7-{4-[(dimethylamino)methyl]piperidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       571   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       572   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(piperidin-1-ylmethyl)piperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       573   2-(3,4-dimethoxyphenyl)-7-{4-[(dimethylamino)methyl]piperidin-1-yl}-4H-pyrido[1,2-           a]pyrimidin-4-one       574   2-(3,4-dimethoxyphenyl)-7-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       575   2-(3,4-dimethoxyphenyl)-7-[4-(piperidin-1-ylmethyl)piperidin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       576   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       577   7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       578   2-(2-methyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       579   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       580   7-(1-ethylpiperidin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       581   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one       582   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{4-[(2-hydroxyethyl)(methyl)amino]piperidin-           1-yl}-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one       583   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[4-(propylamino)piperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       584   7-(4-amino-4-methylpiperidin-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       585   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one       586   2-(2-methyl-2H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one       587   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       588   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-           one       589   2-(2-methyl-2H-indazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one       590   7-(4-ethylpiperazin-1-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one       591   7-[4-(2-hydroxyethyl)piperazin-1-yl]-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       592   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       593   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       594   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-           pyrazino[1,2-a]pyrimidin-4-one       595   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-           pyrazino[1,2-a]pyrimidin-4-one       596   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(ethylamino)piperidin-1-yl]-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       597   7-{4-[bis(2-hydroxyethyl)amino]piperidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-           9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one       598   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrimido[1,2-           b]pyridazin-4-one       599   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-           pyrazino[1,2-a]pyrimidin-4-one       600   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(oxetan-3-yl)piperidin-4-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       601   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       602   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methyloctahydro-5H-pyrrolo[3,2-c]pyridin-           5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       603   2-(1-methyl-1H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       604   7-(1-ethylpiperidin-4-yl)-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       605   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       606   2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       607   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       608   2-(2-methyl-2H-indazol-5-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-           one       609   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{4-[(2-hydroxyethyl)amino]piperidin-1-yl}-9-           methyl-4H-pyrido[1,2-a]pyrimidin-4-one       610   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[4-(methylamino)piperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       611   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[4-(propan-2-ylamino)piperidin-1-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       612   7-(1-ethylpiperidin-4-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       613   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       614   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       615   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       616   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       617   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       618   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-propylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       619   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(propan-2-yl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       620   7-(4-cyclopropylpiperazin-1-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       621   7-(4-cyclobutylpiperazin-1-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       622   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(oxetan-3-yl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       623   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethyloctahydro-5H-pyrrolo[3,2-c]pyridin-5-           yl)-4H-pyrido[1,2-a]pyrimidin-4-one       624   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)octahydro-5H-pyrrolo[3,2-           c]pyridin-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       625   2-(4-methoxy-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       626   2-(4-hydroxy-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       627   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrazino[1,2-           a]pyrimidin-4-one       628   7-(1-cyclobutylpiperidin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       629   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       630   7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       631   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methyl-4-propylpiperazin-1-yl]-           4H-pyrido[1,2-a]pyrimidin-4-one       632   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(2-hydroxyethyl)-3-           methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       633   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       634   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(pyrrolidin-1-yl)piperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       635   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       636   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       637   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       638   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       639   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       640   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       641   7-(1-cyclopropylpiperidin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       642   7-(1-cyclobutylpiperidin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       643   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methyl-4-(propan-2-yl)piperazin-           1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       644   7-[(3R)-4-cyclopropyl-3-methylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-           yl)-4H-pyrido[1,2-a]pyrimidin-4-one       645   7-[(3R)-4-cyclobutyl-3-methylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-           yl)-4H-pyrido[1,2-a]pyrimidin-4-one       646   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methyl-4-(oxetan-3-yl)piperazin-1-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       647   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       648   7-(4-cyclobutylpiperazin-1-yl)-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       649   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-4-(2-hydroxyethyl)-3-           methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       650   7-[(3R)-4-cyclobutyl-3-methylpiperazin-1-yl]-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       651   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-hydroxyethyl)-3-           methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       652   7-[(3S)-4-cyclobutyl-3-methylpiperazin-1-yl]-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       653   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       654   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       655   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       656   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       657   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       658   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       659   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       660   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-propylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       661   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       662   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-fluoroethyl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       663   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(3-fluoropropyl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       664   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(2-fluoroethyl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       665   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(3-fluoropropyl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       666   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(2-fluoroethyl)-3-methylpiperazin-           1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       667   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(3-fluoropropyl)-3-           methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       668   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-fluoroethyl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       669   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(3-fluoropropyl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       670   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{(3R)-4-[2-(2-hydroxyethoxy)ethyl]-3-           methylpiperazin-1-yl}-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one       671   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       672   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methylpiperidin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       673   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(2-hydroxyethyl)-3-methylpiperazin-1-           yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one       674   2-[8-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-6-yl]-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       675   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       676   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       677   2-[8-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-6-yl]-7-(4-methylpiperazin-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       678   7-(4-ethylpiperazin-1-yl)-2-[8-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-6-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       679   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       680   7-(1-cyclopropylpiperidin-4-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       681   7-(1-cyclobutylpiperidin-4-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       682   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(oxetan-3-yl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       683   2-(4-cyclopropyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       684   2-(4-cyclopropyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       685   2-(4-cyclopropyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-ethylpiperazin-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       686   2-(4-cyclopropyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-           4H-pyrido[1,2-a]pyrimidin-4-one       687   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-propylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       688   2-[4-(dimethylamino)-6-methylpyrazolo[1,5-a]pyrazin-2-yl]-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       689   2-(2-methyl-1H-benzimidazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       690   7-(4-ethylpiperazin-1-yl)-2-(2-methyl-1H-benzimidazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       691   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-           one       692   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one       693   7-[1-(2,2-dimethyl-1,3-dioxan-5-yl)piperidin-4-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-           2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       694   7-[1-(1,3-dihydroxypropan-2-yl)piperidin-4-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-           yl)-4H-pyrido[1,2-a]pyrimidin-4-one       695   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       696   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       697   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       698   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       699   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       700   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       701   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       702   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       703   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-9-methyl-           4H-pyrido[1,2-a]pyrimidin-4-one       704   7-(1-cyclobutylpiperidin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       705   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       706   7-[4-(dimethylamino)-4-methylpiperidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       707   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(ethylamino)-4-methylpiperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       708   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-methyl-4-(propylamino)piperidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       709   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{4-[(2-hydroxyethyl)amino]-4-           methylpiperidin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one       710   7-(1-cyclobutylpiperidin-4-yl)-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       711   7-[1-(2-hydroxyethyl)piperidin-4-yl]-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       712   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-propylpiperidin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       713   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       714   2-(8-cyclopropyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       715   2-(8-cyclopropyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       716   2-(8-cyclopropyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       717   2-(8-cyclopropyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-           yl]-4H-pyrido[1,2-a]pyrimidin-4-one       718   7-(1-cyclopropylpiperidin-4-yl)-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       719   7-(1-ethylpiperidin-4-yl)-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       720   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       721   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       722   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(1-methylpiperidin-4-yl)oxy]-4H-pyrido[1,2-           a]pyrimidin-4-one       723   2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       724   7-(4-methylpiperazin-1-yl)-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       725   7-(4-ethylpiperazin-1-yl)-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       726   7-[4-(2-hydroxyethyl)piperazin-1-yl]-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       727   7-[(3R)-3-methylpiperazin-1-yl]-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       728   7-[(3S)-3-methylpiperazin-1-yl]-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       729   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       730   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-[(3R)-3-methyl-4-(propan-2-yl)piperazin-1-yl]-           4H-pyrido[1,2-a]pyrimidin-4-one       731   7-(4-amino-4-methylpiperidin-1-yl)-2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       732   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3S)-3-ethylpiperazin-1-yl]-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       733   2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-7-(piperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       734   7-[(3R)-3-methylpiperazin-1-yl]-2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-           4H-pyrido[1,2-a]pyrimidin-4-one       735   7-[(3S)-3-methylpiperazin-1-yl]-2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-           4H-pyrido[1,2-a]pyrimidin-4-one       736   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-           6-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       737   7-(4-amino-4-methylpiperidin-1-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       738   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       739   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       740   7-(3-aminoprop-1-yn-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       741   2-(2,7-dimethyl-2H-indazol-5-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       742   7-(3-aminopropyl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       743   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       744   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-           4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       745   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(2,2,6,6-tetramethyl-1,2,3,6-           tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       746   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       747   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       748   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(1-ethyl-3-methylpyrrolo[1,2-a]pyrazin-7-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       749   7-(1,4-diazepan-1-yl)-2-(1-ethyl-3-methylpyrrolo[1,2-a]pyrazin-7-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       750   2-(2,7-dimethyl-2H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-           4-one       751   2-(2,7-dimethyl-2H-indazol-5-yl)-7-[(3S)-3,4-dimethylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       752   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       753   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       754   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       755   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       756   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one       757   7-[3-(dimethylamino)azetidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       758   7-[3-(diethylamino)azetidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       759   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[3-(pyrrolidin-1-yl)azetidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       760   7-(1,4-diazepan-1-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       761   7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-(6-methyl-4-propylpyrazolo[1,5-           a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       762   2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       763   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       764   7-[(3S)-3-(aminomethyl)pyrrolidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       765   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[3-(piperidin-1-yl)azetidin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       766   2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       767   7-(2,7-diazaspiro[4.4]non-2-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       768   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       769   7-[3-(dimethylamino)propyl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       770   7-{(3S)-3-[(dimethylamino)methyl]pyrrolidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-           yl)-4H-pyrido[1,2-a]pyrimidin-4-one       771   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       772   9-methyl-2-(1-methyl-1H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       773   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       774   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methylpiperidin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       775   2-(1,7-dimethyl-1H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       776   2-(1,7-dimethyl-1H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       777   2-(1,7-dimethyl-1H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-           4-one       778   7-{(3S)-3-[(diethylamino)methyl]pyrrolidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-           yl)-4H-pyrido[1,2-a]pyrimidin-4-one       779   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{(3S)-3-[(ethylamino)methyl]pyrrolidin-1-yl}-           4H-pyrido[1,2-a]pyrimidin-4-one       780   7-{3-[(dimethylamino)methyl]azetidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       781   7-{3-[(diethylamino)methyl]azetidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       782   2-(1-ethyl-3-methylpyrrolo[1,2-a]pyrazin-7-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       783   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3R)-3-methylpiperazin-1-yl]-           4H-pyrido[1,2-a]pyrimidin-4-one       784   9-methyl-2-(1-methyl-1H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       785   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-           methyl-4H-pyrido[1,2-a]pyrimidin-4-one       786   7-(1-ethylpiperidin-4-yl)-9-methyl-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       787   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]-           4H-pyrido[1,2-a]pyrimidin-4-one       788   7-[1-(2-hydroxyethyl)piperidin-4-yl]-9-methyl-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       789   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-           methyl-4H-pyrido[1,2-a]pyrimidin-4-one       790   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       791   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       792   7-(1-cyclobutylpiperidin-4-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-           pyrido[1,2-a]pyrimidin-4-one       793   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-9-           methyl-4H-pyrido[1,2-a]pyrimidin-4-one       794   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       795   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-           2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       796   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one       797   7-[(3R)-3-(aminomethyl)pyrrolidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       798   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(2S,6S)-2,6-dimethyl-1,2,3,6-           tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one       799   7-{(3R)-3-[(dimethylamino)methyl]pyrrolidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-           yl)-4H-pyrido[1,2-a]pyrimidin-4-one       800   7-[(2S,6S)-2,6-dimethylpiperidin-4-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       836   2-(6-methylimidazo[1,2-a]pyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       837   2′-methyl-7-(piperazin-1-yl)-4H,4′H-2,7′-bipyrido[1,2-a]pyrimidine-4,4′-dione       838   2-[4-(difluoromethoxy)-3-fluorophenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       839   2-(5-fluoro-6-hydroxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       840   2-(4-hydroxy-2-methylquinazolin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       841   2-[6-(dimethylamino)pyridin-3-yl]-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       842   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one       843   2-[4-(dimethylamino)-6-methylpyrazolo[1,5-a]pyrazin-2-yl]-7-(4-methylpiperazin-1-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       844   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[3-(trifluoromethyl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       845   2-(1,7-dimethyl-1H-indazol-5-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       846   2-(1,7-dimethyl-1H-indazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       847   tert-butyl 4-[2-(4-hydroxy-2-methoxyphenyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl]-3,6-           dihydropyridine-1(2H)-carboxylate       848   tert-butyl 4-[2-(2-methoxy-4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)-4-oxo-4H-pyrido[1,2-           a]pyrimidin-7-yl]-3,6-dihydropyridine-1(2H)-carboxylate           849 1     2-[4-(2-hydroxypyridin-4-yl)-2-methoxyphenyl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           850 1     2-[2-hydroxy-4-(2-hydroxypyridin-4-yl)phenyl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       851   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[methyl(2,2,6,6-           tetramethylpiperidin-4-yl)amino]-4H-pyrido[1,2-a]pyrimidin-4-one       852   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[methyl(2,2,6,6-tetramethylpiperidin-           4-yl)amino]-4H-pyrido[1,2-a]pyrimidin-4-one       853   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-           4H-pyrido[1,2-a]pyrimidin-4-one       854   7-(piperazin-1-yl)-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one           855 1     7-(piperazin-1-yl)-2-(1H-pyrazol-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one           856 1     7-[(3S)-3-methylpiperazin-1-yl]-2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       857   2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       858   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           859 1     2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one           860 1     2-(1,7-dimethyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           861 1     2-(1,7-dimethyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           862 1     2-(2,7-dimethyl-2H-pyrazolo[3,4-c]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           863 1     2-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       864   7-(1-ethylpiperidin-4-yl)-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       865   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       866   2-(2,7-dimethyl-2H-indazol-5-yl)-9-methyl-7-(2,2,6,6-tetramethylpiperidin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       867   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(2,2,6,6-tetramethylpiperidin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       868   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       869   2-(7-fluoro-2-methyl-2H-indazol-5-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one           870 1     9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one           871 1     2-(2,7-dimethyl-2H-indazol-5-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-           one       872   7-(1-ethylpiperidin-4-yl)-2-(7-fluoro-2-methyl-2H-indazol-5-yl)-9-methyl-4H-pyrazino[1,2-           a]pyrimidin-4-one       873   7-(1-ethylpiperidin-4-yl)-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one           874 1     2-(2,7-dimethyl-2H-indazol-5-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-pyrazino[1,2-           a]pyrimidin-4-one           875 1     2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       876   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-           pyrazino[1,2-a]pyrimidin-4-one, or       877   7-(1-ethylpiperidin-4-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4H-           pyrazino[1,2-a]pyrimidin-4-one                    
wherein the form of the compound is selected from the group consisting of a salt, prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
     An aspect of the compound of Formula (I) or a form thereof is a compound selected from the group consisting of (where compound number (# 1 ) indicates that a salt form of the compound was isolated):   

                                 Cpd   Name                  836   2-(6-methylimidazo[1,2-a]pyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       837   2′-methyl-7-(piperazin-1-yl)-4H,4′H-2,7′-bipyrido[1,2-a]pyrimidine-4,4′-dione       838   2-[4-(difluoromethoxy)-3-fluorophenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       839   2-(5-fluoro-6-hydroxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       840   2-(4-hydroxy-2-methylquinazolin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       841   2-[6-(dimethylamino)pyridin-3-yl]-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       842   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one       843   2-[4-(dimethylamino)-6-methylpyrazolo[1,5-a]pyrazin-2-yl]-7-(4-methylpiperazin-1-yl)-           4H-pyrido[1,2-a]pyrimidin-4-one       844   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[3-(trifluoromethyl)piperazin-1-yl]-4H-           pyrido[1,2-a]pyrimidin-4-one       845   2-(1,7-dimethyl-1H-indazol-5-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one       846   2-(1,7-dimethyl-1H-indazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-           4-one       847   tert-butyl 4-[2-(4-hydroxy-2-methoxyphenyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl]-3,6-           dihydropyridine-1(2H)-carboxylate       848   tert-butyl 4-[2-(2-methoxy-4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)-4-oxo-4H-           pyrido[1,2-a]pyrimidin-7-yl]-3,6-dihydropyridine-1(2H)-carboxylate           849 1     2-[4-(2-hydroxypyridin-4-yl)-2-methoxyphenyl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           850 1     2-[2-hydroxy-4-(2-hydroxypyridin-4-yl)phenyl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       851   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[methyl(2,2,6,6-           tetramethylpiperidin-4-yl)amino]-4H-pyrido[1,2-a]pyrimidin-4-one       852   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[methyl(2,2,6,6-           tetramethylpiperidin-4-yl)amino]-4H-pyrido[1,2-a]pyrimidin-4-one       853   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-[methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino]-4H-pyrido[1,2-a]pyrimidin-4-one       854   7-(piperazin-1-yl)-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]-4H-pyrido[1,2-           a]pyrimidin-4-one           855 1     7-(piperazin-1-yl)-2-(1H-pyrazol-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one           856 1     7-[(3S)-3-methylpiperazin-1-yl]-2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       857   2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       858   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           859 1     2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one           860 1     2-(1,7-dimethyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           861 1     2-(1,7-dimethyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           862 1     2-(2,7-dimethyl-2H-pyrazolo[3,4-c]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one           863 1     2-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       864   7-(1-ethylpiperidin-4-yl)-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       865   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-           4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one       866   2-(2,7-dimethyl-2H-indazol-5-yl)-9-methyl-7-(2,2,6,6-tetramethylpiperidin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       867   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(2,2,6,6-tetramethylpiperidin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one       868   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one       869   2-(7-fluoro-2-methyl-2H-indazol-5-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one           870 1     9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one           871 1     2-(2,7-dimethyl-2H-indazol-5-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one       872   7-(1-ethylpiperidin-4-yl)-2-(7-fluoro-2-methyl-2H-indazol-5-yl)-9-methyl-4H-           pyrazino[1,2-a]pyrimidin-4-one       873   7-(1-ethylpiperidin-4-yl)-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one           874 1     2-(2,7-dimethyl-2H-indazol-5-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-pyrazino[1,2-           a]pyrimidin-4-one           875 1     2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(piperidin-4-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one       876   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-           pyrazino[1,2-a]pyrimidin-4-one, or       877   7-(1-ethylpiperidin-4-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4H-           pyrazino[1,2-a]pyrimidin-4-one                    
wherein the form of the compound is selected from the group consisting of a salt, prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
 
     Another aspect of the present description includes a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject. 
     Another aspect of the present description includes a use of the compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject. 
     Another aspect of the present description includes a use of the compound salt of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound salt of Formula (I) or a form thereof to the subject. 
     Another aspect of the present description includes a method of use of a compound salt of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound salt of Formula (I) thereof to the subject, wherein the compound salt is selected from the group consisting of: 
                                 Cpd   Name                                        71   2-(3,5-difluoro-4-hydroxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one           hydrochloride (1:1)       203   7-[4-(dimethylamino)piperidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-quinolizin-4-one           acetate (1:1)       380   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one           trifluoroacetate (1:1)       413   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one hydrochloride (1:2)       849   2-[4-(2-hydroxypyridin-4-yl)-2-methoxyphenyl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:1)       850   2-[2-hydroxy-4-(2-hydroxypyridin-4-yl)phenyl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one trifluoroacetate (1:1)       855   7-(piperazin-1-yl)-2-(1H-pyrazol-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one           hydrochloride (1:1)       856   7-[(3S)-3-methylpiperazin-1-yl]-2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one hydrochloride (1:2)       859   2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one hydrochloride (1:2)       860   2-(1,7-dimethyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:2)       861   2-(1,7-dimethyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:2)       862   2-(2,7-dimethyl-2H-pyrazolo[3,4-c]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:2)       863   2-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:2)       870   9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one hydrochloride (1:2)       871   2-(2,7-dimethyl-2H-indazol-5-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one hydrochloride (1:1)       874   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-pyrazino[1,2-           a]pyrimidin-4-one hydrochloride (1:1), or       875   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(piperidin-4-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one hydrochloride (1:2)                    
wherein the form of the compound salt is selected from the group consisting of a prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
 
     An aspect of the compound of Formula (I) or a form thereof is a compound salt selected from the group consisting of: 
                                 Cpd   Name                  849   2-[4-(2-hydroxypyridin-4-yl)-2-methoxyphenyl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:1)       850   2-[2-hydroxy-4-(2-hydroxypyridin-4-yl)phenyl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one trifluoroacetate (1:1)       855   7-(piperazin-1-yl)-2-(1H-pyrazol-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one           hydrochloride (1:1)       856   7-[(3S)-3-methylpiperazin-1-yl]-2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-4H-pyrido[1,2-           a]pyrimidin-4-one hydrochloride (1:2)       859   2-(2-methylpyrazolo[1,5-a]pyridin-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-           one hydrochloride (1:2)       860   2-(1,7-dimethyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:2)       861   2-(1,7-dimethyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:2)       862   2-(2,7-dimethyl-2H-pyrazolo[3,4-c]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:2)       863   2-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-           pyrido[1,2-a]pyrimidin-4-one hydrochloride (1:2)       870   9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one hydrochloride (1:2)       871   2-(2,7-dimethyl-2H-indazol-5-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrazino[1,2-           a]pyrimidin-4-one hydrochloride (1:1)       874   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-pyrazino[1,2-           a]pyrimidin-4-one hydrochloride (1:1), or       875   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(piperidin-4-yl)-4H-           pyrazino[1,2-a]pyrimidin-4-one hydrochloride (1:2)                    
wherein the form of the compound salt is selected from the group consisting of a prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
 
     Chemical Definitions 
     The chemical terms used above and throughout the description herein, unless specifically defined otherwise, shall be understood by one of ordinary skill in the art to have the following indicated meanings. 
     As used herein, the term “C 1-8 alkyl” generally refers to saturated hydrocarbon radicals having from one to eight carbon atoms in a straight or branched chain configuration, including, but not limited to, methyl, ethyl, n-propyl (also referred to as propyl or propanyl), isopropyl, n-butyl (also referred to as butyl or butanyl), isobutyl, sec-butyl, tert-butyl, n-pentyl (also referred to as pentyl or pentanyl), n-hexyl (also referred to as hexyl or hexanyl), n-heptyl (also referred to as heptyl or heptanyl), n-octyl and the like. In some aspects, C 1-8 alkyl includes, but is not limited to, C 1-6 alkyl, C 1-4 alkyl and the like. A C 1-8 alkyl radical is optionally substituted with substituent species as described herein where allowed by available valences. 
     As used herein, the term “C 2-8 alkenyl” generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon double bonds therein, including, but not limited to, ethenyl (also referred to as vinyl), allyl, propenyl and the like. In some aspects, C 2-8 alkenyl includes, but is not limited to, C 2-6 alkenyl, C 2-4 alkenyl and the like. A C 2-8 alkenyl radical is optionally substituted with substituent species as described herein where allowed by available valences. 
     As used herein, the term “C 2-8 alkynyl” generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon triple bonds therein, including, but not limited to, ethynyl, propynyl, butynyl and the like. In some aspects, C 2-8 alkynyl includes, but is not limited to, C 2-6 alkynyl, C 2-4 alkynyl and the like. A C 2-8 alkynyl radical is optionally substituted with substituent species as described herein where allowed by available valences. 
     As used herein, the term “C 1-8 alkoxy” generally refers to saturated hydrocarbon radicals having from one to eight carbon atoms in a straight or branched chain configuration of the formula: —O—C 1-8 alkyl, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy and the like. In some aspects, C 1-8 alkoxy includes, but is not limited to, C 1-6 alkoxy, C 1-4 alkoxy and the like. A C 1-8 alkoxy radical is optionally substituted with substituent species as described herein where allowed by available valences. 
     As used herein, the term “C 3-14 cycloalkyl” generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon radical, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indanyl, indenyl, tetrahydro-naphthalenyl and the like. In some aspects, C 3-14 cycloalkyl includes, but is not limited to, C 3-8 cycloalkyl, C 5-8 cycloalkyl, C 3-10 cycloalkyl and the like. A C 3-14 cycloalkyl radical is optionally substituted with substituent species as described herein where allowed by available valences. 
     As used herein, the term “aryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical, including, but not limited to, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl and the like. An aryl radical is optionally substituted with substituent species as described herein where allowed by available valences. 
     As used herein, the term “heteroaryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S or N atom, including, but not limited to, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, 1,3-thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, isoindolyl, benzofuranyl, benzothienyl, benzoimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, 1,3-diazinyl, 1,2-diazinyl, 1,2-diazolyl, 1,4-diazanaphthalenyl, acridinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 6H-thieno[2,3-b]pyrrolyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, pyrazolo[4,3-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, imidazo[1,2-a]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-b]pyridazinyl, pyrido[1,2-a]pyrimidinyl or pyrido[1,2-a]pyrimidinone and the like. A heteroaryl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences. 
     In certain aspects, the nomenclature for a heteroaryl radical may differ, such as in non-limiting examples where furanyl may also be referred to as furyl, thienyl may also be referred to as thiophenyl, pyridinyl may also be referred to as pyridyl, benzothienyl may also be referred to as benzothiophenyl and 1,3-benzoxazolyl may also be referred to as 1,3-benzooxazolyl. 
     In certain other aspects, the term for a heteroaryl radical may also include other regioisomers, such as in non-limiting examples where the term pyrrolyl may also include 2H-pyrrolyl, 3H-pyrrolyl and the like, the term pyrazolyl may also include 1H-pyrazolyl and the like, the term imidazolyl may also include 1H-imidazolyl and the like, the term triazolyl may also include 1H-1,2,3-triazolyl and the like, the term oxadiazolyl may also include 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl and the like, the term tetrazolyl may also include 1H-tetrazolyl, 2H-tetrazolyl and the like, the term indolyl may also include 1H-indolyl and the like, the term indazolyl may also include 1H-indazolyl, 2H-indazolyl and the like, the term benzoimidazolyl may also include 1H-benzoimidazolyl and the term purinyl may also include 9H-purinyl and the like. 
     As used herein, the term “heterocyclyl” generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with a heteroatom, such as an O, S or N atom, including, but not limited to, oxiranyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, oxadiazolinyl, oxadiazolidinyl, thiadiazolinyl, thiadiazolidinyl, tetrazolinyl, tetrazolidinyl, pyranyl, dihydro-2H-pyranyl, thiopyranyl, 1,3-dioxanyl, 3,6-dihydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,4-diazepanyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, 2,3-dihydro-1,4-benzodioxinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, 1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolyl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazinyl, (8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazinyl, (8aS)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazinyl, (8aR)-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazinyl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, octahydro-2H-pyrido[1,2-a]pyrazinyl, (3aR,4aR,7aS)-hexahydro-1H-cyclobuta[1,2-c:1,4-c′]dipyrrol-(3H)-yl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,6-diazabicyclo[3.2.0]heptyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 4,7-diazaspiro[2.5]octyl, 2,6-diazaspiro[3.4]octyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl, 6,9-diazaspiro[4.5]decyl and the like. A heterocyclyl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences. 
     In certain aspects, the nomenclature for a heterocyclyl radical may differ, such as in non-limiting examples where 1,3-benzodioxolyl may also be referred to as benzo[d][1,3]dioxolyl; 2,3-dihydro-1,4-benzodioxinyl may also be referred to as 2,3-dihydrobenzo[b][1,4]dioxinyl; 2,6-diazaspiro[3.3]heptyl may also be referred to as 2,6-diazaspiro[3.3]heptanyl; 4,7-diazaspiro[2.5]octyl may also be referred to as 4,7-diazaspiro[2.5]octanyl; 2,7-diazaspiro[3.5]nonyl may also be referred to as 2,7-diazaspiro[3.5]nonanyl; and, the like. 
     As used herein, the term “C 1-8 alkoxy-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-O—C 1-8 alkyl. 
     As used herein, the term “C 1-8 alkoxy-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-O—C 1-8 alkyl. 
     As used herein, the term “(C 1-8 alkoxy-C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl-O—C 1-8 alkyl) 2 . 
     As used herein, the term “C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-NH—C 1-8 alkyl-O—C 1-8 alkyl. 
     As used herein, the term “(C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-N(C 1-8 alkyl-O—C 1-8 alkyl) 2 . 
     As used herein, the term “(C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-N(C 1-8 alkyl)(C 1-8 alkyl-O—C 1-8 alkyl). 
     As used herein, the term “C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-NH—C 1-8 alkyl-O—C 1-8 alkyl. 
     As used herein, the term “(C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl-O—C 1-8 alkyl) 2 . 
     As used herein, the term “(C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl)(C 1-8 alkyl-O—C 1-8 alkyl). 
     As used herein, the term “C 1-8 alkoxy-carbonyl” refers to a radical of the formula: —C(O)—O—C 1-8 alkyl. 
     As used herein, the term “C 1-8 alkoxy-carbonyl-C 2-8 alkenyl” refers to a radical of the formula: —C 2-8 alkenyl-C(O)—O—C 1-8 alkyl. 
     As used herein, the term “C 1-8 alkoxy-carbonyl-amino” refers to a radical of the formula: —NH—C(O)—O—C 1-8 alkyl. 
     As used herein, the term “C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl. 
     As used herein, the term “(C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl) 2 . 
     As used herein, the term “C 1-8 alkyl-amino-C 2-8 alkenyl” refers to a radical of the formula: —C 2-8 alkenyl-NH—C 1-8 alkyl. 
     As used herein, the term “(C 1-8 alkyl) 2 -amino-C 2-8 alkenyl” refers to a radical of the formula: —C 2-8 alkenyl-N(C 1-8 alkyl) 2 . 
     As used herein, the term “C 1-8 alkyl-amino-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-NH—C 1-8 alkyl. 
     As used herein, the term “(C 1-8 alkyl) 2 -amino-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-N(C 1-8 alkyl) 2 . 
     As used herein, the term “C 1-8 alkyl-amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-NH—C 1-8 alkyl. 
     As used herein, the term “(C 1-8 alkyl) 2 -amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl) 2 . 
     As used herein, the term “C 1-8 alkyl-amino-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-NH—C 1-8 alkyl. 
     As used herein, the term “(C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-N(C 1-8 alkyl) 2 . 
     As used herein, the term “(C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl-NH—C 1-8 alkyl) 2 . 
     As used herein, the term “[(C 1-8 alkyl) 2 -amino-C 1-8 alkyl] 2 -amino” refers to a radical of the formula: —N[C 1-8 alkyl-N(C 1-8 alkyl) 2]2.    
     As used herein, the term “(C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)(C 1-8 alkyl-NH—C 1-8 alkyl). 
     As used herein, the term “[(C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)[C 1-8 alkyl-N(C 1-8 alkyl) 2 ]. 
     As used herein, the term “C 1-8 alkyl-amino-C 2-8 alkynyl” refers to a radical of the formula: —C 2-8 alkynyl-NH—C 1-8 alkyl. 
     As used herein, the term “(C 1-8 alkyl) 2 -amino-C 2-8 alkynyl” refers to a radical of the formula: —C 2-8 alkynyl-N(C 1-8 alkyl) 2 . 
     As used herein, the term “C 1-8 alkyl-carbonyl” refers to a radical of the formula: —C(O)—C 1-8 alkyl. 
     As used herein, the term “C 1-8 alkyl-carbonyl-amino” refers to a radical of the formula: —NH—C(O)—C 1-8 alkyl. 
     As used herein, the term “C 1-8 alkyl-thio” refers to a radical of the formula: —S—C 1-8 alkyl. 
     As used herein, the term “amino-C 2-8 alkenyl” refers to a radical of the formula: —C 2-8 alkenyl-NH 2 . 
     As used herein, the term “amino-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-NH 2 . 
     As used herein, the term “amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-NH 2 . 
     As used herein, the term “amino-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-NH 2 . 
     As used herein, the term “(amino-C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl-NH 2 ) 2 . 
     As used herein, the term “(amino-C 1-8 alkyl)(C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)(C 1-8 alkyl-NH 2 ). 
     As used herein, the term “amino-C 2-8 alkynyl” refers to a radical of the formula: —C 2-8 alkynyl-NH 2 . 
     As used herein, the term “aryl-C 1-8 alkoxy-carbonyl” refers to a radical of the formula: —C(O)—O—C 1-8 alkyl-aryl. 
     As used herein, the term “aryl-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-aryl. 
     As used herein, the term “aryl-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-aryl. 
     As used herein, the term “(aryl-C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl-aryl) 2 . 
     As used herein, the term “(aryl-C 1-8 alkyl)(C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)(C 1-8 alkyl-aryl). 
     As used herein, the term “aryl-C 1-8 alkyl-amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-NH—C 1-8 alkyl-aryl. 
     As used herein, the term “(aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl-aryl) 2 . 
     As used herein, the term “(aryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl)(C 1-8 alkyl-aryl). 
     As used herein, the term “aryl-amino” refers to a radical of the formula: —NH-aryl. 
     As used herein, the term “aryl-amino-carbonyl” refers to a radical of the formula: —C(O)—NH-aryl. 
     As used herein, the term “aryl-sulfonyloxy-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-O—SO 2 -aryl. 
     As used herein, the term “benzoxy-carbonyl” refers to a radical of the formula: —C(O)—O—CH 2 -phenyl. 
     As used herein, the term “C 3-14 cycloalkyl-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-C 3-14 cycloalkyl. 
     As used herein, the term “C 3-14 cycloalkyl-amino” refers to a radical of the formula: —NH—C 3-14 cycloalkyl. 
     As used herein, the term “C 3-14 cycloalkyl-oxy” refers to a radical of the formula: —O—C 3-14 cycloalkyl. 
     As used herein, the term “halo” or “halogen” generally refers to a halogen atom radical, including fluoro, chloro, bromo and iodo. 
     As used herein, the term “halo-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-halo, wherein C 1-8 alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences. 
     As used herein, the term “halo-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-halo, wherein C 1-8 alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences. 
     As used herein, the term “halo-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-halo. 
     As used herein, the term “(halo-C 1-8 alkyl)(C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)(C 1-8 alkyl-halo). 
     As used herein, the term “(halo-C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl-halo) 2 . 
     As used herein, the term “heteroaryl-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-heteroaryl. 
     As used herein, the term “heteroaryl-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-heteroaryl. 
     As used herein, the term “heteroaryl-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-heteroaryl. 
     As used herein, the term “(heteroaryl-C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl-heteroaryl) 2 . 
     As used herein, the term “(heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)(C 1-8 alkyl-heteroaryl). 
     As used herein, the term “heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-NH—C 1-8 alkyl-heteroaryl. 
     As used herein, the term “(heteroaryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl-heteroaryl) 2 . 
     As used herein, the term “(heteroaryl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl)(C 1-8 alkyl-heteroaryl). 
     As used herein, the term “heteroaryl-amino” refers to a radical of the formula: —NH-heteroaryl. 
     As used herein, the term “heterocyclyl-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-heterocyclyl. 
     As used herein, the term “heterocyclyl-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-heterocyclyl. 
     As used herein, the term “heterocyclyl-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-heterocyclyl. 
     As used herein, the term “(heterocyclyl-C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl-heterocyclyl) 2 . 
     As used herein, the term “(heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)(C 1-8 alkyl-heterocyclyl). 
     As used herein, the term “heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-NH—C 1-8 alkyl-heterocyclyl. 
     As used herein, the term “(heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl-heterocyclyl) 2 . 
     As used herein, the term “(heterocyclyl-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl)(C 1-8 alkyl-heterocyclyl). 
     As used herein, the term “heterocyclyl-amino” refers to a radical of the formula: —NH-heterocyclyl. 
     As used herein, the term “(heterocyclyl)(C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)(heterocyclyl). 
     As used herein, the term “heterocyclyl-amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-NH-heterocyclyl. 
     As used herein, the term “heterocyclyl-carbonyl” refers to a radical of the formula: —C(O)-heterocyclyl. 
     As used herein, the term “heterocyclyl-carbonyl-oxy” refers to a radical of the formula: —O—C(O)-heterocyclyl. 
     As used herein, the term “heterocyclyl-oxy” refers to a radical of the formula: —O-heterocyclyl. 
     As used herein, the term “hydroxy” refers to a radical of the formula: —OH. 
     As used herein, the term “hydroxy-C 1-8 alkoxy-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-O—C 1-8 alkyl-OH. 
     As used herein, the term “hydroxy-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-OH, wherein C 1-8 alkyl is partially or completely substituted with one or more hydroxy radicals where allowed by available valences. 
     As used herein, the term “hydroxy-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-OH. 
     As used herein, the term “(hydroxy-C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl-OH) 2 . 
     As used herein, the term “(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)(C 1-8 alkyl-OH). 
     As used herein, the term “hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N-CalkylC 1-8 alkyl-OH. 
     As used herein, the term “(hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl-OH) 2 . 
     As used herein, the term “(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl” refers to a radical of the formula: —C 1-8 alkyl-N(C 1-8 alkyl)(C 1-8 alkyl-OH). 
     As used herein, the term “hydroxy-C 1-8 alkyl-amino-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-NH—C 1-8 alkyl-OH. 
     As used herein, the term “(hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-N(C 1-8 alkyl-OH) 2 . 
     As used herein, the term “(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkoxy” refers to a radical of the formula: —O—C 1-8 alkyl-N(C 1-8 alkyl)(C 1-8 alkyl-OH). 
     As used herein, the term “hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-NH—C 1-8 alkyl-OH. 
     As used herein, the term “(hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-8 alkyl-NH—C 1-8 alkyl-OH) 2 . 
     As used herein, the term “(hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-N(C 1-8 alkyl-OH) 2 . 
     As used herein, the term “(hydroxy-C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)(C 1-8 alkyl-NH—C 1-8 alkyl-OH). 
     As used herein, the term “[(hydroxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)[C 1-8 alkyl-N(C 1-8 alkyl-OH) 2 ]. 
     As used herein, the term “(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl-amino” refers to a radical of the formula: —NH—C 1-8 alkyl-N(C 1-8 alkyl,C 1-8 alkyl-OH). 
     As used herein, the term “[(hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino-C 1-8 alkyl](C 1-8 alkyl)amino” refers to a radical of the formula: —N(C 1-8 alkyl)[C 1-8 alkyl-N(C 1-8 alkyl)(C 1-8 alkyl-OH)]. 
     As used herein, the term “substituent” means positional variables on the atoms of a core molecule that are substituted at a designated atom position, replacing one or more hydrogens on the designated atom, provided that the designated atom&#39;s normal valency is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. A person of ordinary skill in the art should note that any carbon as well as heteroatom with valences that appear to be unsatisfied as described or shown herein is assumed to have a sufficient number of hydrogen atom(s) to satisfy the valences described or shown. In certain instances one or more substituents having a double bond (e.g., “oxo” or “═O”) as the point of attachment may be described, shown or listed herein within a substituent group, wherein the structure may only show a single bond as the point of attachment to the core structure of Formula (I). A person of ordinary skill in the art would understand that, while only a single bond is shown, a double bond is intended for those substituents. 
     As used herein, the term “and the like,” with reference to the definitions of chemical terms provided herein, means that variations in chemical structures that could be expected by one skilled in the art include, without limitation, isomers (including chain, branching or positional structural isomers), hydration of ring systems (including saturation or partial unsaturation of monocyclic, bicyclic or polycyclic ring structures) and all other variations where allowed by available valences which result in a stable compound. 
     For the purposes of this description, where one or more substituent variables for a compound of Formula (I) or a form thereof encompass functionalities incorporated into a compound of Formula (I), each functionality appearing at any location within the disclosed compound may be independently selected, and as appropriate, independently and/or optionally substituted. 
     As used herein, the terms “independently selected,” or “each selected” refer to functional variables in a substituent list that may occur more than once on the structure of Formula (I), the pattern of substitution at each occurrence is independent of the pattern at any other occurrence. 
     Further, the use of a generic substituent variable on any formula or structure for a compound described herein is understood to include the replacement of the generic substituent with species substituents that are included within the particular genus, e.g., aryl may be replaced with phenyl or naphthalenyl and the like, and that the resulting compound is to be included within the scope of the compounds described herein. 
     As used herein, the terms “each instance of” or “in each instance, when present,” when used preceding a phrase such as “ . . . C 3-14 cycloalkyl, C 3-14 cycloalkyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, heterocyclyl and heterocyclyl-C 1-4 alkyl,” are intended to refer to the C 3-14 cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems when each are present either alone or as a substituent. 
     As used herein, the term “optionally substituted” means optional substitution with the specified substituent variables, groups, radicals or moieties. 
     Compound Forms 
     As used herein, the term “form” means a compound of Formula (I) having a form selected from the group consisting of a free acid, free base, prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof. 
     In certain aspects described herein, the form of the compound of Formula (I) is a free acid, free base or salt thereof. 
     In certain aspects described herein, the form of the compound of Formula (I) is a salt thereof. 
     In certain aspects described herein, the form of the compound of Formula (I) is an isotopologue thereof. 
     In certain aspects described herein, the form of the compound of Formula (I) is a stereoisomer, racemate, enantiomer or diastereomer thereof. 
     In certain aspects described herein, the form of the compound of Formula (I) is a tautomer thereof. 
     In certain aspects described herein, the form of the compound of Formula (I) is a pharmaceutically acceptable form. 
     In certain aspects described herein, the compound of Formula (I) or a form thereof is isolated for use. 
     As used herein, the term “isolated” means the physical state of a compound of Formula (I) or a form thereof after being isolated and/or purified from a synthetic process (e.g., from a reaction mixture) or natural source or combination thereof according to an isolation or purification process or processes described herein or which are well known to the skilled artisan (e.g., chromatography, recrystallization and the like) in sufficient purity to be characterized by standard analytical techniques described herein or well known to the skilled artisan. 
     As used herein, the term “protected” means that a functional group in a compound of Formula (I) or a form thereof is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al,  Protective Groups in organic Synthesis  (1991), Wiley, New York. Such functional groups include hydroxy, phenol, amino and carboxylic acid. Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, methoxymethanol, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. In certain instances, the protecting group may also be a polymer resin, such as a Wang resin or a 2-chlorotrityl-chloride resin. Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art and as described herein. It will also be appreciated by those skilled in the art, although such protected derivatives of compounds described herein may not possess pharmacological activity as such, they may be administered to a subject and thereafter metabolized in the body to form compounds described herein which are pharmacologically active. Such derivatives may therefore be described as “prodrugs”. All prodrugs of compounds described herein are included within the scope of the use described herein. 
     As used herein, the term “prodrug” means a form of an instant compound (e.g., a drug precursor) that is transformed in vivo to yield an active compound of Formula (I) or a form thereof. The transformation may occur by various mechanisms (e.g., by metabolic and/or non-metabolic chemical processes), such as, for example, by hydrolysis and/or metabolism in blood, liver and/or other organs and tissues. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987. 
     In one example, when a compound of Formula (I) or a form thereof contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a functional group such as alkyl and the like. In another example, when a compound of Formula (I) or a form thereof contains a hydroxyl functional group, a prodrug form can be prepared by replacing the hydrogen atom of the hydroxyl with another functional group such as alkyl, alkylcarbonyl or a phosphonate ester and the like. In another example, when a compound of Formula (I) or a form thereof contains an amine functional group, a prodrug form can be prepared by replacing one or more amine hydrogen atoms with a functional group such as alkyl or substituted carbonyl. Pharmaceutically acceptable prodrugs of compounds of Formula (I) or a form thereof include those compounds substituted with one or more of the following groups: carboxylic acid esters, sulfonate esters, amino acid esters, phosphonate esters and mono-, di- or triphosphate esters or alkyl substituents, where appropriate. As described herein, it is understood by a person of ordinary skill in the art that one or more of such substituents may be used to provide a compound of Formula (I) or a form thereof as a prodrug. 
     One or more compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the description herein is intended to embrace both solvated and unsolvated forms. 
     As used herein, the term “solvate” means a physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. As used herein, “solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. 
     As used herein, the term “hydrate” means a solvate wherein the solvent molecule is water. 
     The compounds of Formula (I) can form salts, which are intended to be included within the scope of this description. Reference to a compound of Formula (I) or a form thereof herein is understood to include reference to salt forms thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I) or a form thereof contains both a basic moiety, such as, without limitation an amine moiety, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. 
     The term “pharmaceutically acceptable salt(s)”, as used herein, means those salts of compounds described herein that are safe and effective (i.e., non-toxic, physiologically acceptable) for use in mammals and that possess biological activity, although other salts are also useful. Salts of the compounds of the Formula (I) may be formed, for example, by reacting a compound of Formula (I) or a form thereof with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization. 
     Pharmaceutically acceptable salts include one or more salts of acidic or basic groups present in compounds described herein. Aspects of acid addition salts include, and are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisinate, gluconate, glucaronate, glutamate, iodide, isonicotinate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as tosylate), trifluoroacetate salts and the like. Certain aspects of acid addition salts include chloride, dichloride, trichloride, bromide, acetate, formate or trifluoroacetate salts. 
     Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.)  Handbook of Pharmaceutical Salts. Properties, Selection and Use . (2002) Zurich: Wiley-VCH; S. Berge et al,  Journal of Pharmaceutical Sciences  (1977) 66(1) 1-19; P. Gould,  International J. of Pharmaceutics  (1986) 33, 201-217; Anderson et al,  The Practice of Medicinal Chemistry  (1996), Academic Press, New York; and in  The Orange Book  (Food &amp; Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto. 
     Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium and zinc salts. 
     All such acid salts and base salts are intended to be included within the scope of pharmaceutically acceptable salts as described herein. In addition, all such acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of this description. 
     Compounds of Formula (I) and forms thereof, may further exist in a tautomeric form. All such tautomeric forms are contemplated and intended to be included within the scope of the compounds of Formula (I) or a form thereof as described herein. 
     The compounds of Formula (I) or a form thereof may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. The present description is intended to include all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures. 
     The compounds described herein may include one or more chiral centers, and as such may exist as racemic mixtures (R/S) or as substantially pure enantiomers and diastereomers. The compounds may also exist as substantially pure (R) or (S) enantiomers (when one chiral center is present). In one aspect, the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions substantially comprising only the (S) isomer. In another aspect, the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions substantially comprising only the (R) isomer. As one of skill in the art will recognize, when more than one chiral center is present, the compounds described herein may also exist as a (R,R), (R,S), (S,R) or (S,S) isomer, as defined by IUPAC Nomenclature Recommendations. 
     As used herein, the term “substantially pure” refers to compounds consisting substantially of a single isomer in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100% of the single isomer. 
     In one aspect of the description, a compound of Formula (I) or a form thereof is a substantially pure (S) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%. 
     In one aspect of the description, a compound of Formula (I) or a form thereof is a substantially pure (R) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%. 
     As used herein, a “racemate” is any mixture of isometric forms that are not “enantiomerically pure”, including mixtures such as, without limitation, in a ratio of about 50/50, about 60/40, about 70/30, or about 80/20. 
     In addition, the present description embraces all geometric and positional isomers. For example, if a compound of Formula (I) or a form thereof incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the description. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by use of chiral HPLC column or other chromatographic methods known to those skilled in the art. Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher&#39;s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this description. 
     All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this description, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). Individual stereoisomers of the compounds described herein may, for example, be substantially free of other isomers, or may be present in a racemic mixture, as described supra. 
     The use of the terms “salt”, “solvate”, “ester”, “prodrug” and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or isotopologues of the instant compounds. 
     The term “isotopologue” refers to isotopically-enriched compounds described herein which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as  2 H,  3 H,  13 C,  14 C,  15 N,  18 O,  17 O,  31 P,  32 P,  35 S,  18 F,  35 Cl and  36 Cl, respectively, each of which are also within the scope of this description. 
     Certain isotopically-enriched compounds described herein (e.g., those labeled with  3 H and  14 C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e.,  3 H) and carbon-14 (i.e.,  14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e.,  2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. 
     Polymorphic crystalline and amorphous forms of the compounds of Formula (I) and of the salts, solvates, hydrates, esters and prodrugs of the compounds of Formula (I) are further intended to be included in the present description. 
     Compound Uses 
     The present description relates to a method or use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound or a form thereof to the subject. 
     The present description also relates to a method of use of the compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof. 
     The present description further relates to use of the compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof. 
     The present description further relates to use of the compound of Formula (I) or a form thereof having activity toward HD. 
     The present description further relates to use of the compound of Formula (I) or a form thereof in a combination therapy to provide additive or synergistic activity, thus enabling the development of a combination product for treating or ameliorating HD. 
     In addition to monotherapeutic use, the instant compounds are useful in a combination therapy with current standard of agents, having additive or synergistic activity with one or more known agents. 
     A combination therapy comprising compounds described herein in combination with one or more known drugs may be used to treat HD regardless of whether HD is responsive to the known drug. 
     Aspects of the present description include the use of a compound of Formula (I) or a form thereof in a combination therapy for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof and an effective amount of one or more agent(s). 
     Aspects of the present description include the use of a compound of Formula (I) or a form thereof in a combination therapy for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof and an effective amount of one or more agent(s). 
     In an aspect of a use or method provided herein, compounds of Formula (I) or a form thereof used in combination with one or more additional agents can be administered to a subject or contacted with a subject or patient cell(s) prior to, concurrently with, or subsequent to administering to the subject or patient or contacting the cell with an additional agent(s). A compound(s) of Formula (I) or a form thereof and an additional agent(s) can be administered to a subject or contacted with a cell in single composition or different compositions. In a specific aspect, a compound(s) of Formula (I) or a form thereof is used in combination with gene therapy to inhibit HTT expression (using, e.g., viral delivery vectors) or the administration of another small molecule HTT inhibitor. In another specific aspect, a compound(s) of Formula (I) or a form thereof are used in combination with cell replacement using differentiated non-mutant HTT stem cells. In another specific aspect, a compound(s) of Formula (I) or a form thereof are used in combination with cell replacement using differentiated HTT stem cells. 
     In one aspect, provided herein is the use of compounds of Formula (I) or a form thereof in combination with supportive standard of care therapies, including palliative care. 
     An aspect of the present description includes the use of a compound of Formula (I) or a form thereof in the preparation of a kit comprising the compound of Formula (I) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or a form thereof and an effective amount of one or more agent(s) in a combination therapy for treating or ameliorating HD in a subject in need thereof. 
     Accordingly, the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating HD. In accordance with the use of the present description, compounds that are useful in selectively treating or ameliorating HD, have been identified and use of these compounds for treating or ameliorating HD has been provided. 
     One aspect of the use of the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject. 
     One aspect of the use of the present description relates to a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound to the subject. 
     An aspect of the use of the present description relates to use of a compound of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the medicament to the subject. 
     An aspect of the use of the present description relates to use of a compound of Formula (I) or a form thereof in the preparation of a kit comprising the compound of Formula (I) or a form thereof and instructions for administering the compound for treating or ameliorating HD in a subject in need thereof. 
     In one respect, for each of such aspects, the subject is treatment naive. In another respect, for each of such aspects, the subject is not treatment naive. 
     As used herein, the phrases “a method or use for a compound for treating or ameliorating HD (Huntington&#39;s Disease),” “a method of use for a compound for treating or ameliorating HD” or “a use for a compound for treating or ameliorating HD” coextensively refer to a plurality of potential uses of a compound which would be known to those of skill in the art including, without limitation: (i) a method of use of a compound for treating or ameliorating HD; (ii) a use of a compound for treating or ameliorating HD; (iii) a use of a compound in the preparation of a medicament for treating or ameliorating HD; (iv) a use of a compound in the preparation of a pharmaceutical composition for treating or ameliorating HD; (iv) a use of a compound in the preparation of a kit for treating or ameliorating HD; and, the like. 
     As used herein, the term “treating” refers to: (i) preventing a disease, disorder or condition from occurring in a subject that may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having the disease, disorder and/or condition; (ii) inhibiting a disease, disorder or condition, i.e., arresting the development thereof; and/or (iii) relieving a disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition. 
     As used herein, the term “subject” refers to an animal or any living organism having sensation and the power of voluntary movement, and which requires oxygen and organic food. 
     Nonlimiting examples include members of the human, primate, equine, porcine, bovine, murine, rattus, canine and feline specie. In some aspects, the subject is a mammal or a warm-blooded vertebrate animal. In other aspects, the subject is a human. As used herein, the term “patient” may be used interchangeably with “subject” and “human”. 
     As used herein, the terms “effective amount” or “therapeutically effective amount” mean an amount of compound of Formula (I) or a form, composition or medicament thereof effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect in a subject in need thereof. 
     The dose administered to achieve an effective target plasma concentration may also be administered based upon the weight of the subject or patient. Doses administered on a weight basis may be in the range of about 0.001 mg/kg/day to about 3500 mg/kg/day, or about 0.001 mg/kg/day to about 3000 mg/kg/day, or about 0.001 mg/kg/day to about 2500 mg/kg/day, or about 0.001 mg/kg/day to about 2000 mg/kg/day, or about 0.001 mg/kg/day to about 1500 mg/kg/day, or about 0.001 mg/kg/day to about 1000 mg/kg/day, or about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.001 mg/kg/day to about 250 mg/kg/day, or about 0.001 mg/kg/day to about 100 mg/kg/day, or about 0.001 mg/kg/day to about 75 mg/kg/day, or about 0.001 mg/kg/day to about 50 mg/kg/day, or about 0.001 mg/kg/day to about 40 mg/kg/day, or about 0.001 mg/kg/day to about 30 mg/kg/day, or about 0.001 mg/kg/day to about 20 mg/kg/day, or about 0.001 mg/kg/day to about 10 mg/kg/day, or about 0.01 mg/kg/day to about 2000 mg/kg/day, or about 0.01 mg/kg/day to about 1500 mg/kg/day, or about 0.01 mg/kg/day to about 1000 mg/kg/day, or about 0.01 mg/kg/day to about 600 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 300 mg/kg/day, or about 0.015 mg/kg/day to about 200 mg/kg/day, or about 0.02 mg/kg/day to about 100 mg/kg/day, or about 0.025 mg/kg/day to about 100 mg/kg/day, or about 0.03 mg/kg/day to about 100 mg/kg/day, wherein said amount is orally administered once (once in approximately a 24 hour period), twice (once in approximately a 12 hour period) or thrice (once in approximately an 8 hour period) daily according to subject weight. 
     In certain aspects, the effective amount will be in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.1 mg to about 500 mg/kg/day, or about 1.0 mg/day to about 500 mg/kg/day, in single, divided, or a continuous dose for a patient or subject having a weight in a range of between about 40 to about 200 kg (which dose may be adjusted for patients or subjects above or below this range, particularly children under 40 kg). The typical adult subject is expected to have a median weight in a range of about 70 kg. 
     In another aspect, where daily doses are adjusted based upon the weight of the subject or patient, compounds described herein may be formulated for delivery at about 0.02, 0.025, 0.03, 0.05, 0.06, 0.075, 0.08, 0.09, 0.10, 0.20, 0.25, 0.30, 0.50, 0.60, 0.75, 0.80, 0.90, 1.0, 1.10, 1.20, 1.25, 1.50, 1.75, 2.0, 3.0, 5.0, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 400 or 500 mg/kg/day. 
     Daily doses adjusted based upon the weight of the subject or patient may be administered as a single, divided, or continuous dose. In aspects where a dose of compound is given more than once per day, the dose may be administered twice, thrice, or more times per day. 
     Within the scope of the present description, the “effective amount” of a compound of Formula (I) or a form thereof for use in the manufacture of a medicament, for use in the preparation of a pharmaceutical kit or in a method of use for treating or ameliorating HD in a subject in need thereof is intended to include an amount in a range of from about 0.001 mg/kg/day to about 3500 mg/kg/day, or about 0.001 mg/kg/day to about 3000 mg/kg/day, or about 0.001 mg/kg/day to about 2500 mg/kg/day, or about 0.001 mg/kg/day to about 2000 mg/kg/day, or about 0.001 mg/kg/day to about 1500 mg/kg/day, or about 0.001 mg/kg/day to about 1000 mg/kg/day, or about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.001 mg/kg/day to about 250 mg/kg/day, or about 0.001 mg/kg/day to about 100 mg/kg/day, or about 0.001 mg/kg/day to about 75 mg/kg/day, or about 0.001 mg/kg/day to about 50 mg/kg/day, or about 0.001 mg/kg/day to about 40 mg/kg/day, or about 0.001 mg/kg/day to about 30 mg/kg/day, or about 0.001 mg/kg/day to about 20 mg/kg/day, or about 0.001 mg/kg/day to about 10 mg/kg/day, or about 0.01 mg/kg/day to about 2000 mg/kg/day, or about 0.01 mg/kg/day to about 1500 mg/kg/day, or about 0.01 mg/kg/day to about 1000 mg/kg/day, or about 0.01 mg/kg/day to about 600 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 300 mg/kg/day, or about 0.015 mg/kg/day to about 200 mg/kg/day, or about 0.02 mg/kg/day to about 100 mg/kg/day, or about 0.025 mg/kg/day to about 100 mg/kg/day, or about 0.03 mg/kg/day to about 100 mg/kg/day, wherein said amount is administered once (once in approximately a 24 hour period; i.e., “q.d.”), twice (once in approximately a 12 hour period; i.e., “b.i.d.” or “q.12 h”), thrice (once in approximately an 8 hour period; i.e., “t.i.d.” or “q.8 h”), or four times (once in approximately a 6 hour period; i.e., “q.d.s.”, “q.i.d.” or “q.6 h”) daily according to subject weight. 
     Such amounts may further include an amount in a range of from about 0.001 mg to about 3500 mg administered daily; 0.001 mg to about 3000 mg administered daily; 0.001 mg to about 2500 mg administered daily; 0.001 mg to about 2000 mg administered daily; 0.001 mg to about 1500 mg administered daily; 0.001 mg to about 1000 mg administered daily; 0.001 mg to about 500 mg administered daily; 0.001 mg to about 250 mg administered daily; 1.0 mg to about 3500 mg administered daily; 1.0 mg to about 1500 mg administered daily; 1.0 mg to about 1000 mg administered daily; 10.0 mg to about 600 mg administered daily; 0.5 mg to about 2000 mg administered daily; or, an amount in a range of from about 5.0 mg to about 300 mg administered daily. 
     For example, the effective amount may be the amount required to treat HD in a subject or, more specifically, in a human. The effective amount for a subject will depend upon various factors, including the subject&#39;s body weight, size and health. Effective amounts for a given patient can be determined by routine experimentation that is within the skill and judgment of the clinician. 
     For any compound, the effective amount can be estimated initially either in cell culture assays or in relevant animal models, such as a mouse, chimpanzee, marmoset or tamarin animal model. Relevant animal models may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50  (the dose therapeutically effective in 50% of the population) and LD 50  (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is therapeutic index, and can be expressed as the ratio, LD 50 /ED 50 . In some aspects, the effective amount is such that a large therapeutic index is achieved. In further aspects, the dosage is within a range of circulating concentrations that include an ED 50  with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. 
     More specifically, the concentration-biological effect relationships observed with regard to a compound of Formula (I) or a form thereof indicate a target plasma concentration ranging from approximately 0.001 μg/mL to approximately 50 μg/mL, from approximately 0.01 μg/mL to approximately 20 μg/mL, from approximately 0.05 μg/mL to approximately 10 μg/mL, or from approximately 0.1 μg/mL to approximately 5 μg/mL. To achieve such plasma concentrations, the compounds described herein may be administered at doses that vary, such as, for example, without limitation, from 0.1 ng to 10,000 mg, depending upon the route of administration in single, divided, or continuous doses for a patient weighing between about 10 to about 100 kg (which dose may be adjusted for patients within this weight range, particularly for children under 40 kg). 
     The exact dosage will be determined by the practitioner, in light of factors related to the subject. Dosage and administration may be adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, ethnicity, age, weight, gender, diet, time of day and frequency of administration, drug combination(s), reaction sensitivities, experience with other therapies, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 2, 3 or 4 days, once every week, or once every two weeks depending on half-life and clearance rate of the particular formulation. 
     The compounds and compositions described herein may be administered to the subject via any drug delivery route known in the art. Nonlimiting examples include oral, ocular, rectal, buccal, topical, nasal, sublingual, transdermal, subcutaneous, intramuscular, intraveneous (bolus and infusion), intracerebral, and pulmonary routes of administration. 
     In one aspect, provided herein are methods for modulating the amount of HTT (huntingtin protein), comprising contacting a human cell with a compound of Formula (I) or a form thereof. In a specific aspect, provided herein are methods for modulating the amount of HTT, comprising contacting a human cell with a compound of Formula (I) or a form thereof that modulates the expression of HTT. The human cell can be contacted with a compound of Formula (I) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific aspect, the human cell is from or in a human. In another specific aspect, the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I). 
     In a specific aspect, provided herein is a method for enhancing the inhibition of mutant HTT transcribed from the Htt gene, comprising contacting a human cell with a compound of Formula (I) or a form thereof. The human cell can be contacted with a compound of Formula (I) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific aspect, the human cell is from or in a human. In another specific aspect, the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of wild-type “normal” HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I). 
     In another aspect, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, comprising administering to a non-human animal model for HD a compound of Formula (I) or a form thereof. In a specific aspect, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, comprising administering to a non-human animal model for HD a compound of Formula (I) or a form thereof. In a specific aspect, the compound is a form of the compound of Formula (I). 
     In another aspect, provided herein is a method for decreasing the amount of mutant HTT, comprising contacting a human cell with a compound of Formula (I) or a form thereof. In a specific aspect, provided herein is a method for decreasing the amount of mutant HTT, comprising contacting a human cell with a compound of Formula (I) that inhibits the transcription of mutant HTT (huntingtin mRNA) from the Htt gene. In another specific aspect, provided herein is a method for decreasing the amount of HTT, comprising contacting a human cell with a compound of Formula (I) that inhibits the expression of mutant HTT transcribed from the Htt gene. The human cell can be contacted with a compound of Formula (I) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific aspect, the human cell is from or in a human. In another specific aspect, the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I). 
     In certain aspects, treating or ameliorating HD with a compound of Formula (I) or a form thereof (alone or in combination with an additional agent) has a therapeutic effect and/or beneficial effect. In a specific aspect, treating HD with a compound of Formula (I) or a form thereof (alone or in combination with an additional agent) results in one, two or more of the following effects: (i) reduces or ameliorates the severity of HD; (ii) delays onset of HD; (iii) inhibits the progression of HD; (iv) reduces hospitalization of a subject; (v) reduces hospitalization length for a subject; (vi) increases the survival of a subject; (vii) improves the quality of life for a subject; (viii) reduces the number of symptoms associated with HD; (ix) reduces or ameliorates the severity of a symptom(s) associated with HD; (x) reduces the duration of a symptom associated with HD; (xi) prevents the recurrence of a symptom associated with HD; (xii) inhibits the development or onset of a symptom of HD; and/or (xiii) inhibits of the progression of a symptom associated with HD. 
     Metabolites 
     Also included within the scope of the present description are the use of in vivo metabolic products of the compounds described herein. Such products may result, for example, from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the description includes the use of compounds produced by a process comprising contacting a compound described herein with a mammalian tissue or a mammal for a period of time sufficient to yield a metabolic product thereof. 
     Such products typically are identified by preparing a radio-labeled isotopologue (e.g.,  14 C or  3 H) of a compound described herein, administering the radio-labeled compound in a detectable dose (e.g., greater than about 0.5 mg/kg) to a mammal such as a rat, mouse, guinea pig, dog, monkey or human, allowing sufficient time for metabolism to occur (typically about 30 seconds to about 30 hours), and identifying the metabolic conversion products from urine, bile, blood or other biological samples. The conversion products are easily isolated since they are “radiolabeled” by virtue of being isotopically-enriched (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis. In general, analysis of metabolites may be done in the same way as conventional drug metabolism studies well-known to those skilled in the art. The conversion products, so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds described herein even if they possess no biological activity of their own. 
     Pharmaceutical Compositions 
     Aspects of the present description include the use of a compound of Formula (I) or a form thereof in a pharmaceutical composition for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof in admixture with one or more pharmaceutically acceptable excipient(s). 
     An aspect of the present description includes the use of a pharmaceutical composition of the compound of Formula (I) or a form thereof in the preparation of a kit comprising the pharmaceutical composition of the compound of Formula (I) or a form thereof and instructions for administering the compound for treating or ameliorating HD in a subject in need thereof. 
     As used herein, the term “composition” means a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. 
     The pharmaceutical composition may be formulated to achieve a physiologically compatible pH, ranging from about pH 3 to about pH 11. In some aspects, the pharmaceutical composition is formulated to achieve a pH of from about pH 3 to about pH 7. In other aspects, the pharmaceutical composition is formulated to achieve a pH of from about pH 5 to about pH 8. 
     The term “pharmaceutically acceptable excipient” refers to an excipient for administration of a pharmaceutical agent, such as the compounds described herein. The term refers to any pharmaceutical excipient that may be administered without undue toxicity. Pharmaceutically acceptable excipients may be determined in part by the particular composition being administered, as well as by the particular mode of administration and/or dosage form. Nonlimiting examples of pharmaceutically acceptable excipients include carriers, solvents, stabilizers, adjuvants, diluents, etc. Accordingly, there exists a wide variety of suitable formulations of pharmaceutical compositions for the instant compounds described herein (see, e.g., Remington&#39;s Pharmaceutical Sciences). 
     Suitable excipients may be carrier molecules that include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive antibodies. Other exemplary excipients include antioxidants such as ascorbic acid; chelating agents such as EDTA; carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose (e.g., hydroxypropylmethylcellulose, also known as HPMC), stearic acid; liquids such as oils, water, saline, glycerol and ethanol; wetting or emulsifying agents; pH buffering substances; and the like. Liposomes are also included within the definition of pharmaceutically acceptable excipients. 
     The pharmaceutical compositions described herein may be formulated in any form suitable for the intended use described herein. Suitable formulations for oral administration include solids, liquid solutions, emulsions and suspensions, while suitable inhalable formulations for pulmonary administration include liquids and powders. Alternative formulations include syrups, creams, ointments, tablets, and lyophilized solids which can be reconstituted with a physiologically compatible solvent prior to administration. 
     When intended for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, non-aqueous solutions, dispersible powders or granules (including micronized particles or nanoparticles), emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents, and preserving agents, in order to provide a palatable preparation. 
     Pharmaceutically acceptable excipients suitable for use in conjunction with tablets include, for example, inert diluents, such as celluloses, calcium or sodium carbonate, lactose, calcium or sodium phosphate; disintegrating agents, such as croscarmellose sodium, cross-linked povidone, maize starch, or alginic acid; binding agents, such as povidone, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed. 
     Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example celluloses, lactose, calcium phosphate, or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with non-aqueous or oil medium, such as glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin, or olive oil. 
     In other aspects, pharmaceutical compositions described herein may be formulated as suspensions comprising a compound of Formula (I) or a form thereof in admixture with one or more pharmaceutically acceptable excipient(s) suitable for the manufacture of a suspension. In yet other aspects, pharmaceutical compositions described herein may be formulated as dispersible powders and granules suitable for preparation of a suspension by the addition of one or more excipient(s). 
     Excipients suitable for use in connection with suspensions include suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycethanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate); and thickening agents, such as carbomer, beeswax, hard paraffin, or cetyl alcohol. The suspensions may also contain one or more preservatives such as acetic acid, methyl and/or n-propyl p-hydroxy-benzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin. 
     The pharmaceutical compositions described herein may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth; naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids; hexitol anhydrides, such as sorbitan monooleate; and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent. 
     Additionally, the pharmaceutical compositions described herein may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous emulsion or oleaginous suspension. Such emulsion or suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,2-propanediol. The sterile injectable preparation may also be prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer&#39;s solution and isotonic sodium chloride solution. In addition, sterile fixed oils may be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables. 
     The compounds described herein may be substantially insoluble in water and sparingly soluble in most pharmaceutically acceptable protic solvents and vegetable oils, but generally soluble in medium-chain fatty acids (e.g., caprylic and capric acids) or triglycerides and in propylene glycol esters of medium-chain fatty acids. Thus, contemplated in the description are compounds which have been modified by substitutions or additions of chemical or biochemical moieties which make them more suitable for delivery (e.g., increase solubility, bioactivity, palatability, decrease adverse reactions, etc.), for example by esterification, glycosylation, PEGylation, etc. 
     In some aspects, the compound described herein is formulated for oral administration in a lipid-based composition suitable for low solubility compounds. Lipid-based formulations can generally enhance the oral bioavailability of such compounds. As such, pharmaceutical compositions described herein may comprise a effective amount of a compound of Formula (I) or a form thereof, together with at least one pharmaceutically acceptable excipient selected from medium chain fatty acids or propylene glycol esters thereof (e.g., propylene glycol esters of edible fatty acids such as caprylic and capric fatty acids) and pharmaceutically acceptable surfactants, such as polysorbate 20 or 80 (also referred to as Tween® 20 or Tween® 80, respectively) or polyoxyl 40 hydrogenated castor oil. 
     In other aspects, the bioavailability of low solubility compounds may be enhanced using particle size optimization techniques including the preparation of nanoparticles or nanosuspensions using techniques known to those skilled in the art. The compound forms present in such preparations include amorphous, partially amorphous, partially crystalline or crystalline forms. 
     In alternative aspects, the pharmaceutical composition may further comprise one or more aqueous solubility enhancer(s), such as a cyclodextrin. Nonlimiting examples of cyclodextrin include hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of α-, β-, and γ-cyclodextrin, and hydroxypropyl-β-cyclodextrin (HPBC). In some aspects, the pharmaceutical composition further comprises HPBC in a range of from about 0.1% to about 20%, from about 1% to about 15%, or from about 2.5% to about 10%. The amount of solubility enhancer employed may depend on the amount of the compound in the composition. 
     Preparation of Compounds 
     Compounds of Formula (I) can be prepared using reagents and methods known in the art, including the methods provided in International Application No. PCT/US2013/025292, filed on Feb. 8, 2013, and published as International Publication No. WO 2013/119916 on Aug. 15, 2013, the entire contents of which are incorporated herein by reference (see in particular, General Synthetic Methods, Schemes A-J, at paragraphs [001126] to [001159]; and Specific Synthetic Examples, at paragraphs [001160] to [001573] and Table 1). 
     Biological Examples 
     The following in vitro biological examples demonstrate the usefulness of the compounds of the present description for treating Huntington&#39;s disease. 
     To describe in more detail and assist in understanding the present description, the following non-limiting biological examples are offered to more fully illustrate the scope of the description and are not to be construed as specifically limiting the scope thereof. Such variations of the present description that may be now known or later developed, which would be within the purview of one skilled in the art to ascertain, are considered to fall within the scope of the present description and as hereinafter claimed. 
     Compounds of Formula (I) were tested using the Meso Scale Discovery (MSD) Assay provided in International Application No. PCT/US2016/066042, filed on Dec. 11, 2016 and claiming priority to U.S. Provisional Application 62/265,652 filed on Dec. 10, 2015, published as International Publication No. WO 2017/100726 on Jun. 15, 2017, the entire contents of which are incorporated herein by reference. 
     The Endogenous Huntingtin Protein assay used in Example 1 was developed using the ELISA-based MSD electrochemiluminescence assay platform. 
     Example 1 
     Endogenous Huntingtin Protein Assay 
     Meso Scale Discovery (MSD) 96-well or 384-well plates were coated overnight at 4° C. with MW1 (expanded polyglutamine) or MAB2166 monoclonal antibody (for capture) at a concentration of 1 μg/mL in PBS (30 μL per well). Plates were then washed three times with 300 L wash buffer (0.05% Tween-20 in PBS) and blocked (100 μL blocking buffer; 5% BSA in PBS) for 4-5 hours at room temperature with rotational shaking and then washed three times with wash buffer. 
     Samples (25 μL) were transferred to the antibody-coated MSD plate and incubated overnight at 4° C. After removal of the lysates, the plate was washed three times with wash buffer, and 25 μL of #5656S (Cell signaling; rabbit monoclonal) secondary antibody (diluted to 0.25 μg/mL in 0.05% Tween-20 in blocking buffer) was added to each well and incubated with shaking for 1 Hour at room temperature. Following incubation with the secondary antibody, the wells were rinsed with wash buffer after which 25 μL of goat anti-rabbit SULFO TAG secondary detection antibody (required aspect of the MSD system) (diluted to 0.25 μg/mL in 0.05% Tween-20 in blocking buffer) was added to each well and incubated with shaking for 1 hour at room temperature. After rinsing three times with wash buffer, 150 μL of read buffer T with surfactant (MSD) were added to each empty well, and the plate was imaged on a SI 6000 imager (MSD) according to manufacturers&#39; instructions provided for 96- or 384-well plates. The resulting IC 50  values (μM) for compounds tested are shown in Table 1. 
     As shown in Table 1, test compounds described herein had the following IC 50  values, an IC 50  value between &gt;3 μM and &lt;33 μM is indicated by a single star (*), an IC 50  value between &gt;1 μM and &lt;3 μM is indicated by two stars (**), an IC 50  value between &gt;0.5 μM and &lt;1 μM is indicated by three stars (***), an IC 50  value between &gt;0.1 μM and &lt;0.5 μM is indicated by four stars (****) and an IC 50  value of &lt;0.1 μM is indicated by five stars (*****). 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 1 
               
               
                   
                   
               
               
                   
                 Cpd 
                 IC 50   
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                   
                 29 
                 * 
               
               
                   
                 72 
                 * 
               
               
                   
                 74 
                 ** 
               
               
                   
                 75 
                 ** 
               
               
                   
                 88 
                 * 
               
               
                   
                 94 
                 * 
               
               
                   
                 96 
                 * 
               
               
                   
                 107 
                 * 
               
               
                   
                 108 
                 * 
               
               
                   
                 109 
                 ** 
               
               
                   
                 114 
                 * 
               
               
                   
                 118 
                 * 
               
               
                   
                 120 
                 ** 
               
               
                   
                 121 
                 * 
               
               
                   
                 123 
                 * 
               
               
                   
                 124 
                 * 
               
               
                   
                 125 
                 * 
               
               
                   
                 128 
                 * 
               
               
                   
                 129 
                 * 
               
               
                   
                 131 
                 * 
               
               
                   
                 133 
                 *** 
               
               
                   
                 135 
                 ** 
               
               
                   
                 136 
                 * 
               
               
                   
                 137 
                 ** 
               
               
                   
                 138 
                 ** 
               
               
                   
                 141 
                 ** 
               
               
                   
                 162 
                 * 
               
               
                   
                 163 
                 * 
               
               
                   
                 170 
                 * 
               
               
                   
                 179 
                 * 
               
               
                   
                 191 
                 * 
               
               
                   
                 192 
                 * 
               
               
                   
                 194 
                 * 
               
               
                   
                 199 
                 * 
               
               
                   
                 209 
                 **** 
               
               
                   
                 219 
                 * 
               
               
                   
                 228 
                 * 
               
               
                   
                 229 
                 * 
               
               
                   
                 258 
                 * 
               
               
                   
                 259 
                 * 
               
               
                   
                 261 
                 * 
               
               
                   
                 268 
                 * 
               
               
                   
                 269 
                 *** 
               
               
                   
                 271 
                 ** 
               
               
                   
                 272 
                 *** 
               
               
                   
                 287 
                 **** 
               
               
                   
                 302 
                 **** 
               
               
                   
                 305 
                 **** 
               
               
                   
                 306 
                 **** 
               
               
                   
                 308 
                 *** 
               
               
                   
                 309 
                 ** 
               
               
                   
                 318 
                 ** 
               
               
                   
                 336 
                 * 
               
               
                   
                 337 
                 * 
               
               
                   
                 350 
                 * 
               
               
                   
                 351 
                 * 
               
               
                   
                 356 
                 * 
               
               
                   
                 400 
                 * 
               
               
                   
                 401 
                 * 
               
               
                   
                 409 
                 ** 
               
               
                   
                 410 
                 *** 
               
               
                   
                 412 
                 * 
               
               
                   
                 413 
                 ***** 
               
               
                   
                 420 
                 ** 
               
               
                   
                 421 
                 * 
               
               
                   
                 422 
                 **** 
               
               
                   
                 423 
                 * 
               
               
                   
                 428 
                 * 
               
               
                   
                 438 
                 *** 
               
               
                   
                 441 
                 ** 
               
               
                   
                 442 
                 * 
               
               
                   
                 444 
                 * 
               
               
                   
                 450 
                 * 
               
               
                   
                 451 
                 * 
               
               
                   
                 452 
                 **** 
               
               
                   
                 460 
                 * 
               
               
                   
                 461 
                 * 
               
               
                   
                 462 
                 ** 
               
               
                   
                 463 
                 * 
               
               
                   
                 465 
                 * 
               
               
                   
                 474 
                 *** 
               
               
                   
                 476 
                 * 
               
               
                   
                 477 
                 ** 
               
               
                   
                 479 
                 * 
               
               
                   
                 480 
                 **** 
               
               
                   
                 481 
                 * 
               
               
                   
                 482 
                 * 
               
               
                   
                 486 
                 *** 
               
               
                   
                 487 
                 *** 
               
               
                   
                 489 
                 * 
               
               
                   
                 490 
                 * 
               
               
                   
                 502 
                 ***** 
               
               
                   
                 503 
                 ** 
               
               
                   
                 504 
                 **** 
               
               
                   
                 505 
                 * 
               
               
                   
                 506 
                 * 
               
               
                   
                 507 
                 * 
               
               
                   
                 516 
                 ***** 
               
               
                   
                 530 
                 * 
               
               
                   
                 531 
                 * 
               
               
                   
                 532 
                 ** 
               
               
                   
                 540 
                 ** 
               
               
                   
                 545 
                 * 
               
               
                   
                 546 
                 ** 
               
               
                   
                 549 
                 * 
               
               
                   
                 550 
                 * 
               
               
                   
                 552 
                 * 
               
               
                   
                 553 
                 * 
               
               
                   
                 555 
                 * 
               
               
                   
                 556 
                 * 
               
               
                   
                 557 
                 * 
               
               
                   
                 566 
                 **** 
               
               
                   
                 567 
                 * 
               
               
                   
                 568 
                 ** 
               
               
                   
                 569 
                 ** 
               
               
                   
                 578 
                 * 
               
               
                   
                 579 
                 * 
               
               
                   
                 580 
                 * 
               
               
                   
                 581 
                 ** 
               
               
                   
                 582 
                 * 
               
               
                   
                 584 
                 * 
               
               
                   
                 585 
                 *** 
               
               
                   
                 586 
                 * 
               
               
                   
                 587 
                 **** 
               
               
                   
                 588 
                 *** 
               
               
                   
                 589 
                 * 
               
               
                   
                 590 
                 * 
               
               
                   
                 591 
                 * 
               
               
                   
                 592 
                 * 
               
               
                   
                 593 
                 ** 
               
               
                   
                 594 
                 ** 
               
               
                   
                 595 
                 ** 
               
               
                   
                 599 
                 ** 
               
               
                   
                 606 
                 * 
               
               
                   
                 608 
                 *** 
               
               
                   
                 609 
                 * 
               
               
                   
                 612 
                 ** 
               
               
                   
                 613 
                 ** 
               
               
                   
                 624 
                 *** 
               
               
                   
                 627 
                 ** 
               
               
                   
                 628 
                 * 
               
               
                   
                 632 
                 ** 
               
               
                   
                 633 
                 * 
               
               
                   
                 635 
                 ** 
               
               
                   
                 636 
                 * 
               
               
                   
                 637 
                 *** 
               
               
                   
                 639 
                 * 
               
               
                   
                 641 
                 * 
               
               
                   
                 649 
                 *** 
               
               
                   
                 653 
                 ***** 
               
               
                   
                 654 
                 ***** 
               
               
                   
                 655 
                 **** 
               
               
                   
                 656 
                 **** 
               
               
                   
                 662 
                 *** 
               
               
                   
                 665 
                 * 
               
               
                   
                 667 
                 ** 
               
               
                   
                 668 
                 *** 
               
               
                   
                 671 
                 ** 
               
               
                   
                 673 
                 * 
               
               
                   
                 674 
                 * 
               
               
                   
                 677 
                 * 
               
               
                   
                 679 
                 * 
               
               
                   
                 683 
                 * 
               
               
                   
                 684 
                 * 
               
               
                   
                 685 
                 * 
               
               
                   
                 688 
                 * 
               
               
                   
                 696 
                 ***** 
               
               
                   
                 702 
                 ** 
               
               
                   
                 705 
                 *** 
               
               
                   
                 706 
                 * 
               
               
                   
                 709 
                 * 
               
               
                   
                 710 
                 **** 
               
               
                   
                 711 
                 **** 
               
               
                   
                 713 
                 **** 
               
               
                   
                 714 
                 * 
               
               
                   
                 718 
                 **** 
               
               
                   
                 719 
                 ***** 
               
               
                   
                 720 
                 * 
               
               
                   
                 721 
                 *** 
               
               
                   
                 723 
                 * 
               
               
                   
                 727 
                 * 
               
               
                   
                 733 
                 ** 
               
               
                   
                 734 
                 * 
               
               
                   
                 735 
                 * 
               
               
                   
                 736 
                 * 
               
               
                   
                 738 
                 **** 
               
               
                   
                 739 
                 *** 
               
               
                   
                 741 
                 *** 
               
               
                   
                 748 
                 *** 
               
               
                   
                 749 
                 * 
               
               
                   
                 750 
                 * 
               
               
                   
                 751 
                 * 
               
               
                   
                 752 
                 **** 
               
               
                   
                 753 
                 **** 
               
               
                   
                 754 
                 *** 
               
               
                   
                 755 
                 ** 
               
               
                   
                 756 
                 **** 
               
               
                   
                 763 
                 **** 
               
               
                   
                 766 
                 *** 
               
               
                   
                 768 
                 ** 
               
               
                   
                 770 
                 * 
               
               
                   
                 771 
                 *** 
               
               
                   
                 773 
                 * 
               
               
                   
                 774 
                 * 
               
               
                   
                 776 
                 * 
               
               
                   
                 777 
                 * 
               
               
                   
                 780 
                 ** 
               
               
                   
                 787 
                 * 
               
               
                   
                 791 
                 ***** 
               
               
                   
                 793 
                 ** 
               
               
                   
                 796 
                 ***** 
               
               
                   
                 836 
                 * 
               
               
                   
                 837 
                 * 
               
               
                   
                 838 
                 * 
               
               
                   
                 839 
                 * 
               
               
                   
                 840 
                 * 
               
               
                   
                 841 
                 * 
               
               
                   
                 842 
                 * 
               
               
                   
                 843 
                 * 
               
               
                   
                 844 
                 * 
               
               
                   
                 845 
                 * 
               
               
                   
                 846 
                 * 
               
               
                   
                 847 
                 * 
               
               
                   
                 848 
                 * 
               
               
                   
                 849 
                 * 
               
               
                   
                 850 
                 * 
               
               
                   
                 851 
                 * 
               
               
                   
                 852 
                 * 
               
               
                   
                 853 
                 * 
               
               
                   
                 854 
                 * 
               
               
                   
                 855 
                 * 
               
               
                   
                 856 
                 ** 
               
               
                   
                 857 
                 *** 
               
               
                   
                 858 
                 ** 
               
               
                   
                 859 
                 ** 
               
               
                   
                 860 
                 * 
               
               
                   
                 861 
                 * 
               
               
                   
                 862 
                 ** 
               
               
                   
                 863 
                 ** 
               
               
                   
                 864 
                 ***** 
               
               
                   
                 865 
                 * 
               
               
                   
                 866 
                 * 
               
               
                   
                 867 
                 * 
               
               
                   
                 868 
                 ** 
               
               
                   
                 869 
                 ***** 
               
               
                   
                 870 
                 ***** 
               
               
                   
                 871 
                 ***** 
               
               
                   
                 872 
                 ***** 
               
               
                   
                 873 
                 **** 
               
               
                   
                 874 
                 **** 
               
               
                   
                 875 
                 ***** 
               
               
                   
                 876 
                 ** 
               
               
                   
                 877 
                 ***** 
               
               
                   
                   
               
            
           
         
       
     
     Without regard to whether a document cited herein was specifically and individually indicated as being incorporated by reference, all documents referred to herein are incorporated by reference into the present application for any and all purposes to the same extent as if each individual reference was fully set forth herein. 
     Having now fully described the subject matter of the claims, it will be understood by those having ordinary skill in the art that the same can be performed within a wide range of equivalents without affecting the scope of the subject matter or aspects described herein. It is intended that the appended claims be interpreted to include all such equivalents.